CURRICULUM VITAE

**Date of Revision:** September 14, 2021

**Name:** Sandra Ann Springer, M.D.

**Current title:** Associate Professor, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Clinician Scientist Track, Yale School of Medicine, with a Secondary Appointment in the Yale School of Nursing

**School:** Yale School of Medicine

**Education:**

A.B**.** Harvard University (Psychology) 1990

M.D. University of Massachusetts Medical School 1998

**Career/Academic Appointments:**

1998-1999 Intern, Internal Medicine, Yale-New Haven Hospital, New Haven, CT

1999-2001 Resident, Internal Medicine, Yale-New Haven Hospital, New Haven, CT

2001-2004 Fellow, Infectious Disease, Yale University School of Medicine, New Haven, CT

2004-2008 Clinical Instructor, Department of Medicine, Section of Infectious Disease, Yale School of Medicine, New Haven, CT

2008-2014 Assistant Professor of Medicine, Department of Medicine, Section of Infectious Disease, Yale School of Medicine, New Haven, CT

2009-Present: Attending Physician, Department of Internal Medicine, Section of Infectious Disease, Veterans Administration Connecticut Healthcare System (VACHS)

2014-Present: Associate Professor of Medicine, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine

2014-Present: Associate Clinical Professor of Nursing, Yale School of Nursing

2017-2018: Physician APT Foundation, Inc.

**Administrative Positions:**

2007-2010 Medical Director of Project CONNECT and Project BRIDGE, Yale University Clinical and Community Research, Yale AIDS Program, New Haven, CT

2009- PresentCore Research Scientist, Center for Interdisciplinary Research on AIDS (CIRA), Clinical

 Services Core, Yale School of Medicine and Yale School of Public Health

2009–Present Director, Infectious Diseases Clinic, Veterans Administration Connecticut Healthcare System, Newington Site.

2018- 2020 Vice President of the Connecticut Academy of Arts and Sciences (CAAS)

2019- Present Director of InSTRIDE –Integrating Substance Use Treatment Research with Infectious Disease for Everyone <https://medicine.yale.edu/lab/springer/>

2020- Present NIDA JCOIN LEAP Scholars Program Co-leader

**Board Certification:**

 American Board of Internal Medicine, Internal Medicine, 2001 & 2011

 American Board of Infectious Diseases, 2005, 2015

 American Board of Addiction Medicine, 2010

**Professional Honors & Recognition:**

***International/National/Regional/Local***

2021-Present:Appointed Committee Member for Guidelines for Withdrawal management in Jails as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).

2021- Present:Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)

2019- PresentInvited Member of the NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls

2019 –2020: Appointed to the National Academies of Sciences, Engineering, and Medicine’s Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs

2018 –2020: Invited member of the American Society of Addiction Medicine (ASAM)’s National Practice Guideline Expert Panel for Medication Treatment for OUD

2018- Present: Invited Provider in the SAMHSA STR-TA Consortium to provide assistance to clinicians in the community to treat opioid use disorder

2018- 2020: Invited Vice President of the Connecticut Academy of Arts & Sciences (CAAS)

2018: Invited Planning Committee Member of the *National Academies of Sciences, Engineering and Medicine* (NASEM) Workshop ‘Integrating Infectious Disease Considerations with Response to the Opioid Epidemic’

2017-2020: Invited Member of the IDSA and HIVMA Working Group on Infectious Disease Issues In the Opioid Epidemic

2018: Renewed National Institute of Drug Abuse Independent Scientist Award K02

2015- Present: Active member of Standing NIDA review committee for K99, K12 and T32 Grants

2014-2019: Member of NIDA’s Seek Test Treat and Retain Consortium (STTR)

2014-2019: Co-chair of NIDA’s Seek Test Treat And Retain Committee on HIV Risk Behavior Data Harmonization

2011: National Institute of Drug Abuse Independent Scientist Award K02

2010: Invited Member of the Seek, Test, Treat and Retain Criminal Justice and HIV Modeling Group (STTR CJS), Sponsored by National Institute on Drug Abuse (NIDA)

2007: VNA-South Central Partnership Award for Outstanding Provider in the Community “*that best exemplifies the mission of their organization and recognizes the integral part that nursing plays to the health care team*”.

2006: Recipient of the 2006 B. Jaye Anno Award of Excellence in Communication for:

Altice FL, Springer SA. ‘Overview of HIV Care and Antiretroviral.’ Clinical Practice in Correctional Medicine, 2nd edition. Puissis M. ed. Elsevier Inc. San Diego, CA. 2005

 2005: National Institute of Drug Abuse K23 Mentored Career Development Award

 2002: Bristol-Myers Squibb HIV Virology Fellowship Award

 1998: Academic Excellence Award for Women in Field of Medicine: University of

 Massachusetts Medical School

**Grant/Clinical Trials History:**

**Current Grants**

Agency: NIDA

ID#: 1U01DA053039-01

Title: Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations

**PI: Sandra A. Springer, MD (contact),** Kevin Knight, PhD, Ank Nijhawan, MD

**Role on project: Principal Investigator (contact)**

Percent effort: 20% (concurrent with K02)

Direct costs per year: 2,194,299

Total costs per project period: $11,113,030

Project Period: 09/30/2020-07/31/2025

Agency: NIAAA

ID#: R01AA027976

PI: (Braithwaite, S)

Title: From 90-90-90 to 95-95-95 and beyond: Optimizing and targeting combination HIV prevention for Zimbabwe, eSwatini, and Kwazulu Natal

**Role on project: Co-investigator**

Percent effort: 1% (concurrent with K02)

Direct costs per year: for CT $65,617

Total Costs per project period for CT: $420,120

Project Period: 10/01/19 – 09/30/25

Agency: NIAAA

ID#: R01 18-005067

PI: Scott Braithwaite, MD

**Role on project: Co-investigator**

Title: Could long-acting medications facilitate ‘ending AIDS by 2030’ in southern Africa?)

Role on project: Co-Investigator

Percent effort: 1% (concurrent with K02)

Direct Costs per year: $50,623

Project Period: 10/1/19 – 09/30/ 24

Agency: NIDA

ID#: 1U01DA047982-01

Title: Long-acting buprenorphine vs. naltrexone opioid treatment in CJS-involved adults

PIs: Joshua Lee (contact), **Sandra Springer**, Robert Schwartz, David Farabee, Lisa Marsch, Elizabeth Waddell

**Role on project: Principal Investigator**

Percent Effort: 16% (concurrent with K02)

Direct costs per year: $389,100 (CT)

Total Costs per project period: $17,761,647

Project Period:  08/01/19 – 04/30/24

Agency: NCATS

ID#: 1 U01 TR002763-01

Title: Coordinated medical treatment of opioid use disorder and infectious disease

P**.I.: Sandra Springer (contact),** Edward Nunes, Kathleen Brady, & Frances Levin

**Role on project: Principal Investigator (contact)**

Percent Effort: 10% (concurrent with K02)

Direct Costs per year: $1,170,094

Total Costs per project period: $5,419,179

Project Period: 07/18/19-06/30/23

Agency: National Center for Complementary and Integrative Health

ID#: R61 AT010606

Title: Adapting the HOPE Online Support Intervention to Increase MAT Uptake Among OUD Patients

PI: Sean Young, MD and Sayers, UCI

**Role On Project: Consultant**

Project Period: 08/14/2019- 08/13/23

Agency: NIDA

Study ID: 1 UM1 DA049415-01

Title: CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State

P.I.: El-Bassel N, Feaster D, Gilbert L, Nunes E

**Role on project: co-investigator**

Percent Effort: 1% (concurrent with K02)

Direct cost per year project overall: $12,346,892

Total Costs project overall: $49,387,568

Direct costs per year for CT:    $50,497

Total costs per project period for CT: $267,060

Project Period: 04/17/19-03/31/23

Agency: Veterans Affairs Cooperative Studies Program

Study ID#: Cooperative Study #2014 (CSP 2014)

**Title:** Comparative Effectiveness of Two Formulations of **B**uprenorphine for T**r**e**a**ting Opioid Use Disorder in **Ve**terans(**VA-BRAVE**)

**P. I.: Sandra A. Springer** & Ismene Petrakis

**Role on Project: Principal Investigator**

Percent effort: 20% (VA, has MOU with Yale)

Total Costs per project period: **$**40,922,630

Project Period: 03/31/19-03/30/23

Agency: NIDA

ID#: R61/R33 DA047037

Title: Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders.

**P.I.: Sandra A. Springer (contact)**, Ya-Chi Ho, Yuval Kluger

**Role on project: Principal Investigator (contact).**

Percent Effort: 16% (concurrent with K02)

Direct Costs per year: $500,605

Total costs per project period:  $3,920,900

Project Period: 09/1/18 – 8/30/23

Agency: NIDA

I.D.#: 2K02DA032322

Title:Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection

**P.I. Sandra Springer, MD**
**Role on project: Principal Investigator**

Percent Effort: 75%

Direct costs per year: $114,665

Total Costs per project period: $619,190

Project Period: 05/01/18-04/30/23

Agency: NIH/NIDA

I.D. #: R01DA043337

Title: The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction

**P.I.: Sandra A. Springer, M.D. (contact)** & Albert Shaw, M.D. PhD

**Role on project: Principal Investigator (contact)**

Percent Effort: 10% (concurrent with K02)

Direct Costs per year: $685, 869

Total Costs for project period: $5,756,801

Project Period: 9/1/16-5/31/21, \*No cost Extension through 5/31/22

***Past Grants***

Agency: NIH/NIDA

I.D. # R01 DA033679
Title: Expanding Medication Assisted Therapies (MAT) in Ukraine

P.I.: Frederick L. Altice, M.D.

Role on project: Co-Investigator

Percent Effort: 10%

Direct cost per year: Year 1: $445,311

Total Costs for project period: $2,800,746

Project Period: 04/15/12-03/31/17

Agency: NIH/NIDA

I.D.#R01 DA030762-S1

Title: Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations, Administrative Supplement

P.I.: Sandra A. Springer, MD

Role on project: Principal Investigator

Percent effort: 10%

Direct costs: $90,000

Project Period**: 9/1/15 – 8/31/16**

Agency: NIH/NIDA

I.D. #: K02 DA032322

Title: Mediation Assisted Therapy as a Conduit to Care for HIV+ CJ Populations Transitioning to the Community

PI: Sandra A. Springer, MD

Role on project: Principal Investigator

Percent Effort: 60%

Direct cost per year: Year 1 Direct Costs: $142,810

Total costs for project period: $771,175

Project Period: 07/01/11-06/30/16

Agency: NIH/NIDA

I.D. #: R01 DA030762

Title: Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations

P.I: Sandra A. Springer, M.D.

Role on project: Principal Investigator

Percent Effort: 15%

Direct costs per year: Year 1 Direct Cost: $507,647

Total costs for project period: $4,213,201

Project Period: 09/30/10 – 03/31/16

Agency: NIH/NIDA

I.D. #: R01DA030768

Title: HIV, Buprenorphine, and the Criminal Justice System

P.I. Frederick L. Altice, M.D.

Role on project: Co-Investigator

Percent Effort: 5%

Direct costs per year: Year 1 Direct Cost: $363,311

Total costs for project period: $3,797,572

Project Period: 09/30/10 – 06/30/16

Agency: NIH/NIAAA

I.D. #: R01 AA018944

Title: Alcohol Pharmacotherapies among Released Prisoners.

P.I.: Sandra A. Springer, MD (contact) & Frederick L. Altice, M.D.

Role on project: Principal Investigator

Percent Effort: 15%

Direct costs per year: Year 1 Direct Cost: $459,232

Total costs for project period: $4,457,484

Project Period: 09/30/09 – 08/31/15

Agency: NIH/NIDA

I.D. #: K23 DA 019381

P.I: Sandra A. Springer, M.D.

Title: Opiate Dependence, HIV and Adherence Interventions

PI: Sandra A. Springer, MD

Role on Project: Principal Investigator

Percent Effort: 80%

Total Costs for Project period: $873,520

Project Period: 09/01/05-09/01/10

Agency: NIH/NIDA
I.D. #: R01 DA17059

Title: Project CONNECT: Directly Observed Therapy for Community-Released HIV+ Prisoners

P.I.: Frederick L. Altice, M.D.

Role on project: Medical Director, Co-Investigator

Percent Effort: 50%

Total Costs for Project Period: $3,358,983

Project Period: 09/01/04-06/30/09

Agency: NIH/NIDA

I.D.#: R21 DA019843

Title: Improving Health Outcomes for Released HIV+ Prisoners

P.I.: Frederick L. Altice, M.D.

Role on Project: Project Medical Director/Co-investigator

Percent Effort: 50%

Total Costs for Project Period: $600,000

Project Period: 09/01/05-09/01/07

Agency: Bristol Myers Squib

Title: The Evaluation of Antiretroviral Treatment among HIV+ Prisoners in a Correctional Setting

PI: Sandra A. Springer, MD

Role on Project: Principal Investigator

Percent Effort: 80%

Total award cost: $10,000

Project Period: 07/01/03-06/30/04

# Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale

 **International/National**

2021:Invited Grand Rounds Speaker, University of Rochester School of Medicine, Department of Medicine: Integration of Opioid Addiction and HIV prevention and treatment is Key to Achieving the Goals of the National Ending the HIV Epidemic Plan. July 1, 2021

 2021: Invited Grand Rounds Speaker, Oregon Health Sciences University, Department of Medicine: ‘Yes in My Backyard’ for Integration of Opioid Addiction Treatment with Infectious disease Prevention and Treatment. June 1, 2021

 2021**:** Invited Speaker Ohio State University School of Medicine’s Medical Scientist Training Program. “Integration of infectious disease and opioid use disorder treatment is not only smart but the right thing to do!" February 4, 2021.

 2020: Invited Speaker by NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls:“ *Medication treatment for Addiction and HIV improves Outcomes Upon Release to the Community for Criminal Justice Involved Persons.*” November 20, 2020.

 2020: Invited Speaker by IDSA for *IDWeek 2020. Our Most Challenge Cases:  Impact of COVID-19 on People with HIV and Substance Use Disorders.* October 24, 2020.

2020: Invited Speaker by NIDA: *Addressing risk Through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations* (Springer SA, contact PI) (JCOIN / HIV 042 grant). September 29, 2020.

2020: Invited Presenter. THE AMERICAN SOCIETY OF ADDICTION MEDICINE (ASAM) NATIONAL PRACTICE GUIDELINE FOR THE TREATMENT OF OPIOID USE DISORDER: 2020 FOCUSED UPDATE WEBINAR for INDIVIDUALS IN THE CRIMINAL JUSTICE SYSTEM. September 8, 2020

2020:Invited speaker SUNY Downstate Medical Center’s HIV/ID Research Seminar. *Preventing HIV Outbreaks among People who Inject Drugs in the United States: Integration of opioid and infectious disease prevention and treatment is critical.* October 15, 2020.

2020: Invited Speaker at the Center for Drug Use and HIV Research, New York University. *Integration of Opioid Use Disorder and Infectious Disease Prevention and Treatment: Not only smart but the right thing to do!* June 9, 2020.

2020: Invited Speaker to the O’Neill Institute for National and Global Health Law, Georgetown University Law Center “Promoting the Health of People Who Use Drugs on the Path to Ending the HIV Epidemic.” A convening of the HIV Policy Project. February 19, 2020

 2019: Invited Speaker forthe Connecticut Pharmacist Association, December Continuing Education Program in Bristol CT: Alcohol Use disorders. December 10, 2019

 2019: Invited Speaker National Institute of Alcohol Abuse and Alcoholism (NIAAA) Workshop entitled: *Advancing Uptake, Retention, and Adherence to Antiretroviral Therapy and to Pre-Exposure Prophylaxis (PrEP) for HIV/AIDS Prevention among Alcohol-Using Populations”* workshop September 23-24, 2019. NIH. Bethesda, MD

2019:Invited speaker by National Institute of Drug Abuse (NIDA) to members of NIDA: “*The Opioid and Associated HIV Epidemics: Why Understanding Sex and Gender Differences in Medication Treatments for OUD Matters”.* April 30,2019. Bethesda, MD

 2019: Invited speaker: Johns Hopkins Bloomberg School of Public Health. Johns Hopkins CFAR Adolescent and Young Adults Scientific Working Group (AYA SWG) 4th Annual Spring Symposium: “*HIV/STIs, Substance Use, and the Criminal Justice System… Missed Opportunities for Prevention and Treatment*. April 23, 2019.

 2019: Invited Speaker: National Institutes of Alcohol Abuse and Alcoholism (NIAAA) U13

Alcohol Behavioral HIV Prevention Research: Mechanisms and Intervention Development Conference Program. Discussant of **“***Extension of alcohol challenge studies to investigate mechanisms underlying the association between alcohol consumption, ART adherence, and PrEP uptake”.* January 29-30, 2019. Bethesda, MD.

2018: Invited Speaker for the 2018 National Center for AIDS Research (CFAR) Scientific Symposium, *From Bench to Bedside to Our Own Backyard: Celebrating 20 Years of the CFAR at Emory University School of Public Health,* on Thursday, November 8, 2018. Session: “Tackling Syndemics: Identifying Solutions to the Persistent Crisis of Substance Abuse & HIV.”

 2018: Invited Planning Working Group Member, Moderator and Speaker for the *National Academies of Sciences Engineering and Medicine* (NASEM) *Workshop on Integrating Infectious Disease Considerations with Response to the Opioid Epidemic* convened onMarch 12-13, 2018. Washington, DC. <http://nationalacademies.org/hmd/Activities/PublicHealth/IntegratingInfectiousDiseaseConsiderationswithResponsetotheOpioidEpidemic/2018_MAR-12.aspx>.

2017: Invited Speaker by New England Association of Drug Court Professionals for Conference: *The Drug Courts:  Where Justice and Treatment Meet - Strengthening Community Connections- Conference*. Workshop on medication assisted treatment for opioid use disorder and other Medical Issues within the Criminal Justice System; and a second lecture: Medication Assisted Treatment for the Criminal Justice Population in Drug/Specialty Courts. New England Association of Drug Court Professionals (NEADCP). November 29, 2017. Marlborough, MA

2017: Invited Speaker by the Women Drinking and Pregnancy Work Group of Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (WDP/ICCFASD), National Institute of Alcohol Abuse and Alcoholism (NIAAAA). National Conference on Alcohol and Other Substance Use Among Women and Girls. October 26-27, 2017. Washington, DC

2017:Invited Speaker for Connecticut Pharmacists CME : Title of my talk: An Overview of Medication Assisted Therapies for the Treatment of Opioid Use Disorder. Fall Connecticut Pharmacists Association Continuing Education Program. October 18, 2017. Farmington, CT.

 2017: Invited Speaker by HIV diagnostics and treatment at the Healthcare Committee

Of the Saint Petersburg Government and the Saint Petersburg Center for Prevention and Control of AIDS and Infectious. Scientific conference: ‘Modern Aspects of Prevention, Diagnostics and Treatment of HIV’. October 5-6, 2017. St. Petersburg, Russia.

2017: Invited Speaker by Office of Women’s Healthy, U.S. Department of Health and Human Services. ‘Women and Girls Don't Live in Silos: Integrating HIV/AIDS, Substance Use Disorder & Reproductive HealthScreening & Treatment Methods’. Webinar March 16, 2017.

2016: Invited speaker, 9th Annual International Women’s Conference: Drug treatment as HIV prevention among women who use drugs. Palm Springs, CA, June 10, 2016.

2016: Invited speaker, SAMHSA and NIDA, Non-agonist Treatments- Extended-release Naltrexone Summit, title: Extended-release naltrexone to improve HIV outcomes, at SAMHSA, Bethesda, MD, May 11, 2016.

2016: Invited Web-lecturer: SAMHSA. Drug treatment to improve the HIV continuum of care for Women who use drugs: progress, gaps and future directions, April 27, 2016

2015: Invited lecturer, Columbia School of Social Worker, Drug Treatment as HIV Prevention among Women and Girls who Inject Drugs from a Global Perspective: Progress, Gaps, and Future Direction. New York, NY. Journal of Acquired Immune Deficiencies (JAIDS) Special Issue Event. Sponsored by NIDA. Rethinking the Global Response to the HIV Epidemic Among Women Who Use Drugs: an Urgent Cal to Actions. Columbia School of Social Work. October 30, 2015.

2015: Invited Lecturer Alkermes Inc. Extended-release Naltrexone Summit meeting, Bethesda, MD, March 2015.

2015: Invited lecturer, Howard University. HIV Treatment among Persons with Alcohol and Opioid Use Disorders. June 9, 2015

2014: Invited Speaker, American Psychiatric Association (APA), HIV, substance use and mental illness. San Francisco, CA. November 2, 2014:

2014: Invited Speaker, National Institute of Drug Abuse (NIDA), Project NEW HOPE, Preliminary Results, September 15, 2014.

 2013: Invited Speaker. National Institute of Drug Abuse (NIDA), Seek Test Treat and Retain (STTR) meeting, May 9-10, 2013, Bethesda, MD

 2013: Invited Lecture. Brown University Center for AIDS Research (CFAR)/ Yale CIRA Collaborative Meeting; Invited lecturer “ Medication Assisted Therapy as a Conduit to care fro HIV+ Alcohol and Opioid Dependent Released Criminal Justice Populations”, Miriam Hospital, Providence, RI, January 25, 2013

2012: Invited Speaker, HIV and Corrections and Beyond Symposium, Organizer on Behalf of Center for Interdisciplinary Research on AIDS, XIX International AIDS Conference, Washington, D.C. July 22nd, 2012.

2011: Invited Speaker by NIDA and the International Workshop on Treatment as Prevention, (TasP), Vancouver, Canada. May 4-6, 2011.

2010: Invited Presenter, National Institute of Drug Abuse (NIDA), Seek Test Treat and Retain in the Criminal Justice System. Bethesda, MD.

 2010: Invited Presenter by National Institute of Drug Abuse (NIDA), Substance Abuse Interventions as A Conduit to Care for HIV+ persons within the Criminal Justice System, at National Institute of Drug Abuse (NIDA), HIV, Technology and Adherence Symposium. Bethesda, MD.

 2009: Invited Presenter, Alcohol Pharmacotherapies for HIV-infected Released Prisoners,

 National Institute on Alcoholism and Alcohol Abuse (NIAAA), Bethesda, MD.

 **Regional**

2021: New England AIDS Education and Training Center (NAETC) and the National Alliance for HIV Education and Workforce Development.. May 11, 2021.

2021: New England AIDS Education and Training Center (NAETC) and the National Alliance for HIV Education and Workforce Development and the Opioid Response Network interactive webinar titled “Connecticut Response to the Triple Threat: HIV, HCV and Substance Use Disorder”.Long-acting Medication Treatments for Opioid Use Disorder: Potential implications to improve the HIV and HCV Cascades of Care. January 19, 2021

2020: VA Project ECHO. PrEP for persons who Use drugs. May 11, 2020.

2017: PrEP for persons with Substance Use Disorders. VACHS Addiction Psychiatry Services. November 14, 2017.

2017: Medication assisted therapy for Opioid Use Disorder. National Committee of Pharmacists. Farmington, CT. October 28, 2017.

2017: VA PrEP for Veterans. Invited Speaker for Community Based Providers, VACHS. January 26, 2017.

2016: VA PRIME Center Invited Speaker. Extended-release naltrexone reduces alcohol consumption and maintains VL suppression among released prisoners living with HIV after release to the community: Results of a randomized controlled trial. November 14, 2016.

2016: Pre- Exposure Prophylaxis, Invited lecturer, VACHS, Primary Care Physicians, May 3, 2016.

2013: The use of Extended-Release Naltrexone to reduce drinking for DUI offenders, presented to CT department of Probation, Hartford, CT

2012:Extended-Release Naltrexone as a conduit to care for released criminal justice populations: Invited to present to Connecticut Department of Corrections, Hartford, CT.

2011: The Center for Translational Neuroscience of Alcoholism, West Haven, CT. Invited to present research on medication assisted therapy.

2010: Connecticut Department of Public Health AIDS & Chronic Diseases Section Invited to present "Substance abuse and HIV interactions”

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale**

 **International/National**

2021:MacNamara K, Biondi B, Hernández-Ramírez R, Taweh N, Grimshaw A, **Springer SA**. Infectious Disease Outcomes among Persons with Opioid Use Disorder Treated with Buprenorphine, Methadone or Extended-Release Naltrexone: A Systematic Review and Meta-Analysis. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021:Biondi B, VanderWyk B, Shaw A, **Springer SA**. An Evaluation of Factors Associated with Retention on Medication Treatment for Opioid Use Disorder among a Cohort of Persons Seeking Treatment in the Community. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021: Waddell EN, Baker R, Collins DR, Bialas S, Hartung DM, Hildebran CJ, Korthuis PT, Kunkel LE, Larsen J, Lee JD, **Springer S**, Stack E, Nguyen T, Wisdom J, Meyer D. Reducing Overdose After Release from Incarceration (ROAR): Preliminary Findings from the Pre-Pandemic Cohort. College on Problems of Drug Dependence (CPDD) Virtual 2021 Conference. June 2021.

2021: Biondi B, Frank C, **Springer S.** Gender Differences Among Justice-Involved Persons Living with HIV and Opioid and Alcohol Use Disorders Interested in Extended-Release Naltrexone Treatment" 14th Academic and Health Policy on Conference on Correctional Health. Poster Presentation. Virtual Presentation. April 10, 2021.

2021:Grammatico, M.,Moll, AP., Choi, K., **Springer, S.,** Shenoi, SV. HIV Pre-exposure prophylaxis (PrEP) Uptake Among Alcohol Users in Rural South Africa. Poster accepted at 4th HIV Research for Prevention Conference; 2021 January 27 – 28; Cape Town, South Africa.

2020: Grammatico, M**.,** Moll, AP., **Springer, S.**, Choi, K., Shenoi, SV. Pre-exposure prophylaxis (PrEP) short-term retention among heavy alcohol users in rural South Africa. Poster accepted at IDWeek 2020; 2020 October 21-25; Philadelphia, Pennsylvania (Virtual due to COVID19 Pandemic).

2020**:** Cioe K, Biondi B, Easly R, Simard A, Xheng X, **Springer SA**. A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder. AMERSA conference. October 2020 (Virtual due to COVID19 Pandemic).

2020:Cioe K, Biondi B, Easly R, Simard A, **Springer SA**. A Systematic Review of Patient and Provider Perspectives of Medications for Treatment of Opioid Use Disorder. International Conference On Opioids. August 2020 (Virtual due to COVID19 Pandemic).

2020**:** NIDA’sSTTR consortium (includes **Springer S**). Association Of Individual And Polysubstance Use, Including Binge Alcohol Use, On Condom Use Behavior In A Multi-Site Cohort. Abstract #757. Research Society on Alcoholism conference (RSA). June 21-24, 2020. (Virtual Conference due to COVID19 pandemic).

 2020: Taweh N, Biondi B, **Springer S**. Gender Differences Among Persons with OUD Starting Treatment with Methadone or Buprenorphine. *12th International Women’s and Children’s Health and Gender (InWomen’s) Group* conference. Hollywood, Florida, USA June 19, 2020 (Virtual Due to COVID19 pandemic).

2020: Seval N, Marotta P, Biondi B & **Springer S**. Injection Drug Use Risk Behaviors Among Persons involved in the Criminal Justice System With Opioid Use Disorder: A Secondary Analysis. Accepted Oral Presentation. 13th Academic and Health Policy Conference on Correctional Health, Raleigh, NC. April 2-3, 2020.

2020: Biondi B, Frank C, **Springer S.** Gender Differences Among Justice-Involved Persons Living with HIV and Opioid and Alcohol Use Disorders Interested in Extended-Release Naltrexone Treatment" 13th Academic and Health Policy on Conference on Correctional Health. Poster Presentation. April 2-3, 2020 Raleigh, NC.

2019: **Springer S** &Barocas J, Co-Moderators; Thornton A, Thakarar K, Hurley H & Wurcel A, Symposium Presenters: *Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Response*. IDWeek *2019* Symposium. Washington, DC. October 2, 2019.

2019: Thakor N & **Springer S.** A novel mathematical simulation to study the effect of naltrexone on CD4 cells, CD8 cells, and HIV viral load. Abstract ID# 564. 81st Annual College on Problems of Drug Dependence (CPDD). San Antonio, TX. June 18, 2019.

2019: Biondi, B & **Springer S.** Change in Risk Behaviors Among Recently Released Prisoners Living with HIV and Substance Use Disorders. Oral Abstract Number: 4050. 12th Annual Academic & Health Policy Conference on Correctional Healthcare. March 21-22, 2019. Las Vegas, NV.

2018: **S. Springer**. Alcohol pharmacotherapies to improve alcohol and HIV treatment outcomes after release from prison for women living with HIV and Alcohol Use Disorders in the United States Criminal Justice System; Part of Invited Speaker for Oral Symposium: Alcohol and HIV: closing interdisciplinary gaps and building research agenda for global interdisciplinary research to improve health and child outcomes. Organizer: Tatiana Balachova, NIAAA. Chair, Kendall Bryant, NIAAA. Speakers Ralph DiClemente, Lynn Matthews, Shirish Barve, Anait Marianian, **Sandra Springer**. 19th Congress of International Society for Biomedical Research on Alcoholism (ISBRA 2018) September 10, 2018 in Kyoto, Japan.

2018: **S Springer**. Medication Assisted Treatment For Alcohol Use Disorder To Improve The HIV Continuum Of Care For Women Involved In The Criminal Justice System; Part of Oral Symposium: ‘Women Hold Up Half The Sky: The Evidence From Global Research On Alcohol And HIV Interventions’.  Organizer: Tatiana Balachova, NIAAA and Chair: Wendee Wechsberg. Speakers: **Sandra Springer**, Geetanjaili Chander, Som Bohora, & Deidra Roach (NIAAA). Research Society on Alcoholism (RSA). San Diego, CA, June 19, 2018.

**2018: J Wagman, M Matsuzaki, N Gnatienko, LR Metsch, C Del Rio, DJ Feaster, JAC Delaney, X Dong, S Kahana, HM Crane, R Chandler, JC Elliott, F Altice, G Lucas, S Mehta, Y Hirsch-Moverman, W El-Sadr, V Quan, S Springer, E Pitpitan, J Tsui, Jh Samet. Associations Between Hazardous Alcohol Use, Antiretroviral Receipt And Viral Suppression In HIV-Positive People Who Inject Drugs In The U.S., India, Russia, Vietnam. Poster Abstract. Research Society on Alcoholism (RSA). San Diego, CA. June 16-20, 2018.**

2018: **S Springer**, M Azar, , R Barbour, B Biondi, M Herme, F Altice, A Dipaola. Extended-release Naltrexone Improves viral suppression among HIV+ Prisoners. **Oral** abstract 96. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, March 4-7, 2018.

2017: **S Springer**, R Barbour, MM Azar, M Herme, T Winn, FL Altice, A Di Paola. Results of a Double Blind Placebo Controlled Randomized Trial of Extended-Release Naltrexone Among HIV+ Inmates with Opioid Dependence. Conference and Proceedings on Drug Dependence (CPDD). **Oral** Presentation. Montreal, Canada. June 17-18, 2017. June 20, 2017.

2017**: S Springer,** MM Azar, R Barbour, FL Altice, and A Di Paola. Results of a Double Blind Placebo Controlled Randomized Trial of Extended-Release Naltrexone Among HIV+ Inmates with Alcohol Use Disorders. Conference and Proceedings on Drug Dependence (CPDD). **Late Breaker Oral Presentation**. Montreal, Canada. June 17-18, 2017. June 21, 2017.

2017: Beckwith, I. Kuo, R. Young, R. Fredericksen, L. Brinkley-Rubinstein, W. Cunningham, J. Franks, C. Zawitz, D. Seal, **S. Springer**, K. Christopoulos, J. Lorvick, B. Kruszka, J.A. Delaney, H. Crane, S. Kahana, M.L. Biggs. Similar HIV Care Indicators among HIV-Infected Transgender Women and Cisgender Males: Data from the “Seek, Test, Treat, and Retain” Harmonization Initiative. 12th International Conference on HIV Treatment and Prevention. June 4-6, 2017. Miami, FL. June 3-5.

 2017: Cunningham W, Nance R, **Springer S,** Golin C, Kruszka B, Whitney B, Franks J, Lorvick J, Lucas G, Wechsberg W, Clemenzi-Allen A, Crane H, Delaney J. Associations of Self-reported ART Adherence with Viral Load in HIV+ Criminal Justice-Involved Populations. Abstract number 187. 12th International Conference on HIV Treatment and Prevention. June 4-6, 2017. Miami, FL. June 3-5.

2017: Kelsey B. Loeliger, Mary L. Biggs, Rebekah Young, Shoshana Y. Kahana, David W. Seal, Curt G. Beckwith, Irene Kuo, Michael S. Gordon, Lawrence J. Ouellet, William E. Cunningham, Jeremy D. Young, **Sandra A. Springer.** Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A Seek, Test, Treat, and Retain Harmonization. Abstract number 2086. 10th Academic and Health Policy on Conference on Correctional Health (Atlanta, GA). March 16-17, 2017.

2016**: Springer S,** Azar M, Barbour R, Altice FL, DiPaola A. Extended-release Naltrexone improves HIV Viral load suppression among HIV+ released prisoners with alcohol use disorders. **Late breaker** poster abstract. 21th International AIDS Conference. Durban, South Africa. July 20, 2016.

2016**: Springer S,** Azar M, Barbour R, Krishnahan A, Altice FL, DiPaola A. Extended-release naltrexone increases time to heavy drinking among HIV+ released prisoners with alcohol use disorders. **Oral** Abstract. 21th International AIDS Conference. Durban, South Africa. July 20, 2016.

2016: Mary-Ellen Mackesy-Amiti, Lauren Strand, Robin Nance, William Cunningham, Elise Riley, Chinazo Cunningham, Chuck Cleland, Lisa Metsch, Daniel Feaster, Carlos del Rio, Bridget Kruszka, **Sandra Springer**. An example of exposure heterogeneity when pooling epidemiologic studies for meta-analysis of antiretroviral medication adherence. Abstract 507. 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management August 25-29, 2016. Dublin, Ireland

2015: Loeliger, KB, Biggs, ML, Seal, DW, Gordon, MS, Beckwith, CG, Kuo I, Young JD, Golin CE, Chandler R, Wechsberg WW, Altice FL, **Springer SA**. Gender Differences in Sexual Risk Behaviors Among HIV-infected and Uninfected persons involved in the U.S. Criminal Justice System: The STTR Harmonization Project. Abstract NO. 1497. 2015 National HIV Prevention Conference. December 6-9, 2015, Atlanta, GA.

2015:**Springer SA.** Drug Treatment as HIV Prevention among Women and Girls who Inject Drugs from a Global Perspective: Progress, Gaps, and Future Direction. New York, NY. JAIDS Special Issue Event. Rethinking the Global Response to the HIV Epidemic Among Women Who Use Drugs: an Urgent Cal to Actions. Columbia School of Social Work. October 30, 2015

2015**: Springer SA*.*** Prevention of relapse to Opioid use as a means to improve HIV treatment outcomes.6th Annual Prescription Drug Abuse Symposium, Indianapolis, IN. October 28-29, 2015. Oral presentation.

2015:**Springer SA**, DiPaola A, Altice FL. Acceptability of Extended-Release Naltrexone as a conduit to care for HIV+ Criminal Justice populations. 2015 National Summit on HCV and HIV Diagnosis, Prevention, and Access to Care. June 4-6, 2015. Arlington, VA.

2015: Strand L, Nance R, Chandler R, Cunningham W, Riley E, Mehta S, Altice F, Wechsberg W, Cunningham C, Cleland C & **Springer S.** Initial data harmonization in the STTR HIV Consortium: evaluating the relationship between antiretroviral adherence and substance use. Society for Epidemiologic Reesearch (SER) Annual Meeting. Denver, Co. June 18, 2015. Poster session 5

2015: Lee J, **Springer SA**, Friedman P, Farabee D, Schwartz R, & Chandler R. Opioids, CJS Populations, and Medication Assisted Treatment: Jail, Prison, and Community CJS Clinical Trials. Oral Symposium.8th Academic and Health Policy Conference on Correctional Health. March 20, 2015. Boston, MA.

2015: Krishnan A, DiPaola A, Altice FL, **& Springer SA**. Extended-release naltrexone to reduces relapse to alcohol use for HIV-infected prisoners transitioning to the community.Abstract. 8th Academic and Health Policy Conference on Correctional Health. March 19-20, 2015. Boston, MA

2014: **Springer, SA,** Smith D, Nwulia E & Lawson, W**.** Treating the Triple Whammy: Substance Abuse, Mental Illness and HIV/AIDS. Symposium**.** Abstract No: 252. 66th American Psychiatric Association (APA) Institute on Psychiatric Services (IPS) Conference. October 30-November 2, 2014. San Francisco, CA.

2014:Vagenas P, Zelenev A, Di Paola A, Altice FL, **Springer SA**. Retention in Care Among HIV infected Black Men Who Have Sex with Men Before and After Release from Jail: Results from a Multi-site Study. Abstract #365. 9th International Conference on HIV Treatment and Prevention Adherence; June 8-102014; Miami, FL.

2014: **Springer SA**, Wohl DA, Gordon MS, Kahana SY, Chandler RK.  Presentation Title: Seek, Test, Treat, and Retain: Addressing HIV in the Criminal Justice System Presenters. 7th Academic and Health Policy Conference on Correctional Health March 21-22, 2014 in Houston, Texas. Submission ID: 18153

2014: **Springer SA**, Taxman F, Mbaba M, Wooditch A, Jones D. Presentation title: Client and Systems Issues: Addressing Special Population Health Needs of Justice-Involved Individuals. 7th Academic and Health Policy Conference on Correctional Health March 21-22, 2014, Houston, Texas. Submission ID: 18190.

2014: Meyer J, Cepeda J, Wu J, Trestman R, Altice F, **Springer SA.** Longitudinal Treatment Outcomes in HIV-Infected Prisoners and Influence of Re-Incarceration**.** Conference on Retroviruses and Opportunistic Infections (CROI); March3-6, 2014; Boston MA. Poster Abstract: P-W2.

2013: **Springer SA,** Gastfriend D, Woody, G, Lee J. Symposium: Medication Assisted Therapy: Adaptability and Durability. International Society of Addiction Medicine, Kuala Lumpur, Malaysia, November 21-23, 2013.

2013: **Springer SA**, McCarty D, Lee G, Crevecoeur-MacPhail, D, Chalk M. Oral Symposium: Extended-release Naltrexone: Emerging data on effectiveness and cost-effectiveness. Addiction Health Services Research Meeting, October 23-25, 2013, Portland, Oregon.

2013: Di Paola A, Altice FL, **Springer SA**. A DSM-IV Mental Illness Evaluation of a Cohort of HIV Infected Prisoners Transitioning to the Community. Abstract No 16427. 6th Academic and Health Policy Conference on Correctional Health, March 21-22, 2013; Chicago, Illinois.

 2012: **Springer SA**, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoner.Abstract presentation number WEPE 330. XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012.

2012: Lima V, Spaulding A, Kim B, Stein M, Messina L, Beckwith C, Wong J, Bazerman L, Montaner J, Graf I, Isaei A, Coombs D, Altice F, **Springer S,** Winn T, Herma M, Powers K, Wohl D, Erinoff L, Normand J, Seek Test Treat and Retain Corrections (STTaR Corr) Modeling Group. Modeling the impact of implementing a Seek, Test, Treat, and Retain (STTR) strategy to halt epidemic within the Criminal Justice System (CJS) in different regions in the US. Poster Presentation. Abstract No. THPE105. XIX International AIDS Conference. July 22-27, 2012. Washington, D.C.

2012**: Springer SA.** Implementing Extended-Release Naltrexone among Alcohol and Opioid Dependent Released Criminal Justice Populations. Symposium, oral presentation. 2012 SAAS conference and NIATx Summit, June 19-22, 2012. New Orleans, LA.

2012: **Springer SA.** Extended-release Naltrexone for HIV+ released prisoners. Chair and Presenter of Oral Symposium. Research Society on Alcoholism (RSoA) Scientific Meeting in San Francisco CA, June 23-27.

 2012: **Springer SA,** Nightingale V, Taxman F, Tangney J. Cross-discipline Treatment Approaches for Mental Health and Substance Related Issues for Offenders. Academic & Health Policy Conference on Correctional Health. Oral symposium presentation. March 22-23, 2012. Atlanta, Georgia.

2012: Normand J, Erinoff L, Volkow N, Spaulding A, Altice F, **Springer SA**, Herme M, Wohl D, Powers K, Beckwith C, Rich J, Lima VD, Nosyk B, Montaner J, Coombs D, Issaei A, Graf I. Modeling the Impact of Implementing a Test and Treat Strategy within the US Criminal Justice System. The 2nd Treatment as Prevention Meeting, Vancouver, Canada. April 2012. Oral Abstract.

2011: Chen NE, Meyer JP, Avery AK, Draine J, Flanigan T, Lincoln TP, Spaulding A, **Springer SA**, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees; 6th International Conference on HIV Treatment and Prevention Adherence, May 22-24, 2011; Miami Beach FL. Abstract Presentation 69889.

2011: Altice FL, Saber-Tehrani AS, Qui J, Herme M, **Springer SA**. Directly Administered Antiretroviral Therapy (DAART) is Superior to Self-Administered Therapy (SAT) Among Released HIV+ Prisoners: Results from a Randomized Controlled Trial (RCT); 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27-March 2, 2011; Boston MA. Abstract Presentation.

2009: **Springer SA**, Chen S, Altice FL. A Prospective Clinical Trial of Buprenorphine Administered As Relapse-Prevention Treatment For Release HIV-Infected Prisoners. " 4th International Conference on HIV Treatment Adherence; April 5-7, 2009; Miami, FL. Oral Abstract 0237.

2009: **Springer SA**, Chen S, Altice, FL. Depression and Symptomatic Response Among HIV-Infected Drug Users Enrolled in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. 4th International Conference on HIV Treatment Adherence. ; April 5-7, 2009; Miami, FL. Oral Abstract 0239.

2009: Maru Smith-Rohrberg D, Bruce R, Walton M, **Springer SA**, Altice FL. Waning of Virological Benefits Following Directly Administered Antiretroviral Therapy among Drug Users: Results from a Randomized, Controlled Trial. 16th Conference on Retroviruses and Opportunistic Infections (CROI); February 8-11, 2009; Montreal, Canada. Abstract 579.

2003: Altice FL, Mezger J, Bruce D, **Springer S**, Hodges J, Friedland GH. Preliminary Results of a Randomized Trial (RCT) of Modified Enhanced Directly Administered Antiretroviral Therapy (mDAART+) vs. Standard of Care Therapy (SAT): A Model for Administration of ART in Marginalized Populations. Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA); October 9-12, 2003; San Diego, CA. Abstract 655.

2003: **Springer S**, Hodges J, Doros G, Pesanti E, Altice FL. Effectiveness of HAART in HIV-Infected Prisoners. Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA); October 9-12, 2003; San Diego, CA. Abstract 652.

2003: Altice FL, Mezger J, Hodges J, Bruce D**, Springer S**, Friedland GH. Directly observed therapy (DOT) for HIV+ drug users (IUDs). Program and abstracts of the 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 40.

1994: Teoh SK, Mendelson JH, Mello NK, Eros-Sarnyai M, Skupny A, **Springer SA**. Dopaminergic responsivity and prolactin levels in cocaine and heroin dependent men: A pilot study. NIDA Research Monograph, Problems of Drug Dependence. Proceedings of the 56th Annual Scientific Meeting, College on Problems of Drug Dependence, (CPDD). 1994.

**Professional Service:**

***Peer Review Groups/Grant Study Sections:***

2021: Invited NIDA R01 reviewer June 28, 2021

2020: Invited NIDA R01 and K08 reviewer November 18, 2020

2020: INVITED K99 GRANT REVIEWER NIDA/ NIAAA JUNE 15, 2020

2020: INVITED AHRQ REVIEWER JUNE 10, 2020

2020: Invited Chair of NIDA Clinical Trial Network (CTN) grant reviews**.**

2019: Invited DSMB member review committee for NIDA CTN study proposals

2019: Invited Chair of the NIDA Justice Community Opioid Innovation Network (JCOIN) HEAL grant review

2019: Invited co-chair for NIDA Clinical Trial Network (CTN)Node HEAL grant review

2018: Invited member of review panel Advancing Exceptional Research on HIV/AIDS and Substance Abuse

2018: K99/K12/T32 Section meeting, Study section reviewer NIDA October 15-1

2018: Invited member of the Interventions to Prevent and Treat Addictions (IPTA) study section, October 4-5, 2018

2018: Member of K99/K12/T32 Study Section, NIDA

2017: Member of K99/K12/T32 Study Section, NIDA

2016: Invited Reviewer of R18 and R01 Grants for AHRQ

2016: Invited Reviewer of U01 by NIAID

2016: Invited Reviewer of R01 Grants for NIDA

` 2016: Invited Reviewer of AHQR grant reviews

2016: Invited Chair of R01 STTR Youth grant, NIDA

2016: Invited reviewer K99 grants for NIDA (Spring, Summer, Fall sessions)

2015: Invited reviewer of K99, K12 and T32 Grants for NIDA

2015- PresentStandingMember of K99/K12/T32 Study Section, NIDA

2014: Invited Reviewer of R21 & R01 Grants for National Institute of Drug Abuse, (NIDA), February

2013: Invited Reviewer of R25/T32 Grants for National Institute of Drug Abuse (NIDA), December

2012: Invited Reviewer of R01 Grants for Center for Scientific Review (CSR),

2012 Invited Reviewer of R01 Grants for National Institute of Drug Abuse (NIDA), December, November

2012 Invited Reviewer of R01 Grants for National Institute of Drug Abuse (NIDA), October

2012 Invited Reviewer of R01 Grants for National Institute of Alcoholism and Alcohol Abuse (NIAAA), July 2012

2011 Invited Reviewer of Grants for National Institute of Drug Abuse (NIDA), February 2011

2009- Present:Center for Interdisciplinary Research on AIDS (CIRA), Core Review Committee

**Advisory Boards**

**2021-Present** Appointed Committee Member for Guidelines for Withdrawal management in Jails as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).

**2021- Present:** Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)

**2021- Present:** Appointed DSMB Member for *NIDA UG3 DA047720 (IND 134996) A Pharmacokinetic Study of Vivitrol in Healthy Participants (GM00191*). PI Adam Bisaga, M.D., Columbia University

**2020- Present**: Appointed DSMB Member for NIDA Clinical Trials Network (CTN) 0080: *Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing two buprenorphine formulations.* Theresa Winhusen, Ph.D, PI, U of Cincinnati College of Medicine.

**2019-Present:** DSMB member for CDC funded Project ROAR; PI, Elizabeth Waddell, PhD, OHSU**.**

**2019-Present:** DSMB member forA Pilot Pharmacokinetic Trial of the O’Neil Long Acting

Injectable Naltrexone Implant (Study GM0017). PIs Adam Bisaga, MD & Edward Nunes, MD, Columbia U.

 **2019- Present:** Appointed Member of the NIAAA/NIDA Interagency Work Group on Drinking and Drug Use in Women and Girls

 **2019:** Appointed NIDA Clinical Trials Network (CTN) DSMB member for CTN 001 and 0097. July 22, 2019- September 30 2019.

**2019 – 2020:** Appointed to the National Academies of Sciences, Engineering, and Medicine’s (the Academies) Committee on “Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs”

**2018 – Present:** Invited member of the American Society of Addiction Medicine’s (ASAM) National Practice Guideline Expert Panel for Medication Treatment for OUD

**2018- Present:** Invited member of the SAMHSA State Targeted Response Technical Assistance (STR-TA) program Provide assistance to clinicians for treating patients with Opioid Use Disorder.

 **2018:** Invited Planning Working Group Member and Moderator for the *National Academies of Sciences, Engineering and Medicine* (NASEM) *Workshop on Integrating Infectious Disease Considerations with Response to the Opioid Epidemic* convened onMarch 12-13, 2018. Washington, DC. <http://nationalacademies.org/hmd/Activities/PublicHealth/IntegratingInfectiousDiseaseConsiderationswithResponsetotheOpioidEpidemic/2018_MAR-12.aspx>.

 **2017-2020:** Invited Member of the Infectious Disease Society of America (IDSA) and HIVMA Working Group On Infectious Disease Issues In the Opioid Epidemic

 **2017**: Patient Clinical Support Services (PCSS) Medication Assisted Therapy (MAT) Extended-release Naltrexone Protocol

 **2016-2017:** American Society of Addiction Medicine (ASAM). Public Policy for Hepatitis C

Infection. Invited member of writing group. October 2016. <https://urldefense.proofpoint.com/v2/url?u=https-3A__www.asam.org_docs_default-2Dsource_public-2Dpolicy-2Dstatements_pdff5b01a9472bc604ca5b7ff000030b21a.pdf-3Fsfvrsn-3D0&d=DwMFAg&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZopE7HOKuU2n8SXi_pzFgKRQ-ELYdmO9zoe94a6WH9k&m=AQ6RlUCpcrpSBY-Q8QKgMasKr8Yc8xuyHjzG0zSgS2g&s=99gsh42L047R1hCcwGFXeaNYvlrhQPPEUyzxBKdIc04&e>

**Journal Service:**

***Editorial Boards:***

2020 - Present, Invited Associate Editor, Contemporary Clinical Trials

2021 - Present, Invited Editorial Advisory Board, Open Forum of Infectious Diseases

***Reviewer:***

***2007-Present****:* Addiction

Addiction Biology

AIDS

 AIDS and Behavior

 AIDS Care

 Alcoholism Experimental & Clinical Research

American Journal of Drug and Alcohol Abuse

 American Journal of Psychiatry (AJP)

American Journal of Public Health (AJPH)

 Annals of Internal Medicine

 British Medical Journal (BMJ)

 BMC ID

 BMJ Open

 Clinical Infectious Diseases (CID)

 Contemporary Clinical Trials

 Drug and Alcohol Dependence

 HIV Clinical Trials

 Infectious Disease Clinics of North America

 International Journal of Drug Policy

 International J of HIV and STDS

 International J of Prison Health

Journal of Acquired Immune Deficiency Syndrome (JAIDS)

Journal of Addiction Medicine (JAM)

 Journal of the American Medical Association (JAMA)

 Journal of Substance Abuse Treatment (JSAT)

 Journal of Women’s Health

 Open Forum Infectious Disease (OFID)

 PLoS ONE

 New England Journal of Medicine (NEJM)

 The Lancet

 The Lancet Infectious Disease

 The Lancet HIV

 Substance Use Journal

***Professional Service for Professional Organizations:***

2021-Present:Appointed Committee Member for Guidelines for Withdrawal management in Jails as part of collaboration between American Society of Addiction Medicine (ASAM), the National Commission on Correctional Health Care (NCCHC) and the Department of Justice /Bureau of Justice Agency (BJA).

2021- Present:Invited Appointed member of American Society of Addiction Medicine (ASAM) Criminal Justice Guideline Committee (CJGC)

2021- Present:Appointed DSMB Member for *NIDA UG3 DA047720 (IND 134996) A Pharmacokinetic Study of Vivitrol in Healthy Participants (GM00191*). PI Adam Bisaga, M.D., Columbia University

2020- Present: Appointed DSMB Member for NIDA Clinical Trials Network (CTN) 0080: *Medication treatment for Opioid use disorder in expectant Mothers (MOMs): a pragmatic randomized trial comparing two buprenorphine formulations.* Theresa Winhusen, Ph.D, PI, U of Cincinnati College of Medicine.

2019-Present: DSMB member for CDC funded Project ROAR; PI, Elizabeth Waddell, PhD, OHSU**.**

2019-Present: DSMB member forA Pilot Pharmacokinetic Trial of the O’Neil Long Acting

 Injectable Naltrexone Implant (Study GM0017). PIs Adam Bisaga, MD & Edward Nunes, MD, Columbia U.

2019:Appointed NIDA Clinical Trials Network (CTN) DSMB member for CTN 001 and 0097. July 22, 2019- September 30, 2019.

2019- Present: Appointed Member of the NIAAA/NIDA Interagency Working Group on Drinking and Drug Use in Women and Girls

2019- March2020: Appointed to the National Academies of Sciences, Engineering, and Medicine’s (the Academies) Committee on “Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs

2018-2020: Invited member of the American Society of Addiction Medicine (ASAM) National Practice Guideline Expert panel for Medication Treatment for Opioid Use Disord

2018- 9/2020: Vice President, Connecticut Academy of Arts & Sciences (CAAS)

2018- Present: Selected Expert as Recovery Consultant for the State Targeted response Technical Assistance Program (STR-TA) Consortium funded by SAMHSA to provide expertise in treatment of opioid use disorders with medications.

2017-Present: Invited Member of the IDSA and HIVMA Working Group On Infectious Disease Issues In the Opioid Epidemic

2017-Present: Regular member of Conference on Problems of Drug Dependence (CPDD)

2014- Present: Co-chair of NIDA’s Seek Test Treat And Retain Committee on HIV Risk Behavior Data Harmonization

2010-Present: Invited member of Seek, Test, Treat and Retain Criminal Justice and HIV Modeling Group (STTR CJS), National Institute on Drug Abuse (NIDA/NIH)

2009-Present: Center for interdisciplinary Research on AIDS (CIRA), Yale School of Medicine, and Elected Core Research Scientist

 2006-Present: Member, American Society of Addiction Medicine

 2003-Present: Member, HIV Medical Association

2003-2015: Medical Care and Call service for Infectious Disease Patients in theConnecticut Department of Corrections.

2001-Present: Member, Infectious Diseases Society of America

**Public Service:**

2004-2015 Community Health Care Van, Provided volunteer clinical care, assistance and oversight.

2018- Present Recovery Consultant for the State Targeted response Technical Assistance Program (STR- TA) Consortium funded by SAMHSA to provide expertise in treatment of opioid use disorders with medications.

**Bibliography:**

**Peer-Reviewed Original Research**

1. Teoh SK, Sarnyai Z, Mendelson JH, Mello NK, **Springer SA**, Sholar JW, Wapler M, Kuehnle JC, Gelles H. Cocaine effects on pulsatile secretion of ACTH in men. Journal of Pharmacological Experiments and Theories. 1994; 270 (3): 1134-8. PMID: 7932162.
2. Levin JM, Holman BL, Mendelson JH, Teoh SK, Garada B, Johnson KA**, Springer SA**. Gender Differences in Cerebral Perfusion in Cocaine Abuse: Technetium-99m-HMPAO SPECT Study of Drug-Abusing Women. Journal of Nuclear Medicine. 1994; 35 (12):1902-9. PMID: 7989967.
3. **Springer SA** & Gastfriend DR. A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. Journal of Addictive Disorders 1995; 14(2): 53-66. PMID: 8541360.
4. Altice FL, **Springer SA**, Buitrago, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal of Urban Health: Bulletin of New York Academy of Medicine 2003; 80(3): 416-427. PMID: 12930880; PMCID: PMC3455979.
5. Altice FL, Mezger J, Hodges J, Bruce RD, Marinovich A, Walton M, **Springer SA**, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: implications for program replication. Clinical Infectious Diseases. 2004; 38: S376-87. PMID: 15156426.
6. **Springer SA,** Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases. 2004; 38(12):1754-1760. PMID: 15227623.
7. Altice FL, Marinovich A, Khoshnood K, Blankenship KM, **Springer SA**, Selwyn PA. Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection. Journal of Urban Health. 2005; 82(2):312-26. PMID: 15872190; PMCID: PMC3456574.
8. **Springer SA** & Altice FL. Managing HIV in correctional settings. Current HIV/AIDS Reports. 2005; 2:165-170. PMID: 16343373.
9. **Springer SA**, Friedland G, Doros, G, Pesanti E, Altice F. Antiretroviral treatment regimens outcomes among HIV-Infected prisoners. HIV Clinical Trials. 2007; 8(4):205-12. PMID: 17720660; PMCID: PMC2409059.
10. Altice FL, Maru D, Bruce RD, **Springer SA**, Friedland G. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-Infected drug users: A prospective, randomized controlled trial. Clinical Infectious Diseases. 2007; 45(6): 770-8. PMID: 17712763; PMCID: PMC2693907.
11. Maru, DS, Kozal MJ, Bruce RD, **Springer SA**, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized, controlled trial. Journal of the Acquired Immune Deficiency. 2007;15;46(5):555-63. PMID: 18193497; PMCID: PMC2684061.
12. Maru DS, Bruce RD, Walton M, Mezger JA, **Springer SA**, Shield D, Altice FL. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS and Behavior. 2008; 12(2):284-93. PMID: 18085432; PMCID: PMC2693908.
13. **Springer SA** & Bruce RD. A pilot survey of attitudes and knowledge of opioid substitution therapy for HIV-infected prisoners. Journal of Opiate Management. 2008; 4(2): 81-86. PMID: 18557164; PMCID: PMC2476214.
14. Maru DS, Bruce RD, Walton M, **Springer SA,** Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: Results from a randomized, controlled trial. Journal of the Acquired Immune Deficiency. 2009; 1;50(2):176-81. PMID: 19131891; PMCID: PMC2670996.
15. **Springer SA**, Chen S, Altice FL. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009; 21; 8: 976-983. PMID: 20024753; PMCID: PMC2797133.
16. **Springer SA,** Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of Buprenorphine treatment. Journal of Urban Health. 2010; 87(4): 592-602. PMID: 20177974; PMCID: PMC2900572.
17. Anand P, **Springer SA,** Copenhaver M, Altice FL. Neurocognitive impairment and HIV risk factors: A reciprocal relationship. AIDS and Behavior. 2010; 14(6): 1213-26. PMID: 20232242; PMCID: PMC2906682.
18. Azar MM, **Springer SA**, Meyer JP & Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug and Alcohol Dependence; 112:178-193. PMID: 20705402; PMCID: PMC2997193.
19. **Springer SA**, Azar MM, Altice FL. HIV and alcohol dependence: A Call for evidence-based treatments for released prisoners. American Journal of Drug and Alcohol Abuse. 2010; 37(1); 12-21. PMID: 21171933; PMCID: PMC3070290.
20. Meyer JP, **Springer SA**, Altice FL. Substance abuse, violence, and HIV in women: A literature review of the syndemic. Journal of Women’s Health. 2011; 20(7). PMID: 21668380; PMCID: PMC3130513.
21. Chen NE, Meyer JP, **Springer SA**. Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infectious Disease Reports 2011; 3:e6; 20-29. PMID: 23745166; PMCID: PMC3671603.
22. Meyer JP, Chen NE, **Springer SA.** HIV Treatment in the criminal justice system: Critical knowledge and intervention gaps. AIDS Research and Treatment, 2011 680617. Epub 2011 Jul 12. PMID: 21776379; PMCID: PMC3137962.
23. Granich R, Gupta S, Suthar AB, Smyth C, [Hoos D](http://www.ncbi.nlm.nih.gov/pubmed?term=Hoos%20D%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Vitoria M](http://www.ncbi.nlm.nih.gov/pubmed?term=Vitoria%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Simao M](http://www.ncbi.nlm.nih.gov/pubmed?term=Simao%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Hankins C](http://www.ncbi.nlm.nih.gov/pubmed?term=Hankins%20C%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Schwartlander B](http://www.ncbi.nlm.nih.gov/pubmed?term=Schwartlander%20B%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Ridzon R](http://www.ncbi.nlm.nih.gov/pubmed?term=Ridzon%20R%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Bazin B](http://www.ncbi.nlm.nih.gov/pubmed?term=Bazin%20B%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Williams B](http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20B%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Lo YR](http://www.ncbi.nlm.nih.gov/pubmed?term=Lo%20YR%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [McClure C](http://www.ncbi.nlm.nih.gov/pubmed?term=McClure%20C%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Montaner J](http://www.ncbi.nlm.nih.gov/pubmed?term=Montaner%20J%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Hirnschall G](http://www.ncbi.nlm.nih.gov/pubmed?term=Hirnschall%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21999779), [Welte A](http://www.ncbi.nlm.nih.gov/pubmed?term=Welte%20A&cauthor=true&cauthor_uid=21999779), [End A](http://www.ncbi.nlm.nih.gov/pubmed?term=End%20A&cauthor=true&cauthor_uid=21999779), [Duerr A](http://www.ncbi.nlm.nih.gov/pubmed?term=Duerr%20A&cauthor=true&cauthor_uid=21999779), [Kurth A](http://www.ncbi.nlm.nih.gov/pubmed?term=Kurth%20A&cauthor=true&cauthor_uid=21999779), [del Rio C](http://www.ncbi.nlm.nih.gov/pubmed?term=del%20Rio%20C&cauthor=true&cauthor_uid=21999779), [Gordon C](http://www.ncbi.nlm.nih.gov/pubmed?term=Gordon%20C&cauthor=true&cauthor_uid=21999779), [Celum CL](http://www.ncbi.nlm.nih.gov/pubmed?term=Celum%20CL&cauthor=true&cauthor_uid=21999779), [Beckwith C](http://www.ncbi.nlm.nih.gov/pubmed?term=Beckwith%20C&cauthor=true&cauthor_uid=21999779), [Seal DW](http://www.ncbi.nlm.nih.gov/pubmed?term=Seal%20DW&cauthor=true&cauthor_uid=21999779), [Wohl D](http://www.ncbi.nlm.nih.gov/pubmed?term=Wohl%20D&cauthor=true&cauthor_uid=21999779), [Havlir DV](http://www.ncbi.nlm.nih.gov/pubmed?term=Havlir%20DV&cauthor=true&cauthor_uid=21999779), [Mills E](http://www.ncbi.nlm.nih.gov/pubmed?term=Mills%20E&cauthor=true&cauthor_uid=21999779), [Malitz F](http://www.ncbi.nlm.nih.gov/pubmed?term=Malitz%20F&cauthor=true&cauthor_uid=21999779), [Marks G](http://www.ncbi.nlm.nih.gov/pubmed?term=Marks%20G&cauthor=true&cauthor_uid=21999779), [Caswell G](http://www.ncbi.nlm.nih.gov/pubmed?term=Caswell%20G&cauthor=true&cauthor_uid=21999779), [Van Cutsem G](http://www.ncbi.nlm.nih.gov/pubmed?term=Van%20Cutsem%20G&cauthor=true&cauthor_uid=21999779), [Colfax G](http://www.ncbi.nlm.nih.gov/pubmed?term=Colfax%20G&cauthor=true&cauthor_uid=21999779), [Kuo I](http://www.ncbi.nlm.nih.gov/pubmed?term=Kuo%20I&cauthor=true&cauthor_uid=21999779), [Sikazwe I](http://www.ncbi.nlm.nih.gov/pubmed?term=Sikazwe%20I&cauthor=true&cauthor_uid=21999779), [Neaton JD](http://www.ncbi.nlm.nih.gov/pubmed?term=Neaton%20JD&cauthor=true&cauthor_uid=21999779), [Mermin J](http://www.ncbi.nlm.nih.gov/pubmed?term=Mermin%20J&cauthor=true&cauthor_uid=21999779), [Amon J](http://www.ncbi.nlm.nih.gov/pubmed?term=Amon%20J&cauthor=true&cauthor_uid=21999779), [Rich J](http://www.ncbi.nlm.nih.gov/pubmed?term=Rich%20J&cauthor=true&cauthor_uid=21999779), [De Cock K](http://www.ncbi.nlm.nih.gov/pubmed?term=De%20Cock%20K&cauthor=true&cauthor_uid=21999779), [Ouellet LJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Ouellet%20LJ&cauthor=true&cauthor_uid=21999779), [Metsch L](http://www.ncbi.nlm.nih.gov/pubmed?term=Metsch%20L&cauthor=true&cauthor_uid=21999779), [van Deth L](http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Deth%20L&cauthor=true&cauthor_uid=21999779), [Gardner LI](http://www.ncbi.nlm.nih.gov/pubmed?term=Gardner%20LI&cauthor=true&cauthor_uid=21999779), [Santoro MM](http://www.ncbi.nlm.nih.gov/pubmed?term=Santoro%20MM&cauthor=true&cauthor_uid=21999779), [Newell ML](http://www.ncbi.nlm.nih.gov/pubmed?term=Newell%20ML&cauthor=true&cauthor_uid=21999779), [Harrington M](http://www.ncbi.nlm.nih.gov/pubmed?term=Harrington%20M&cauthor=true&cauthor_uid=21999779), [Gordon MS](http://www.ncbi.nlm.nih.gov/pubmed?term=Gordon%20MS&cauthor=true&cauthor_uid=21999779), [Das M](http://www.ncbi.nlm.nih.gov/pubmed?term=Das%20M&cauthor=true&cauthor_uid=21999779), [Ford N](http://www.ncbi.nlm.nih.gov/pubmed?term=Ford%20N&cauthor=true&cauthor_uid=21999779), [Garg N](http://www.ncbi.nlm.nih.gov/pubmed?term=Garg%20N&cauthor=true&cauthor_uid=21999779), [Keiser O](http://www.ncbi.nlm.nih.gov/pubmed?term=Keiser%20O&cauthor=true&cauthor_uid=21999779), [Cherutich P](http://www.ncbi.nlm.nih.gov/pubmed?term=Cherutich%20P&cauthor=true&cauthor_uid=21999779), [Cohen RM](http://www.ncbi.nlm.nih.gov/pubmed?term=Cohen%20RM&cauthor=true&cauthor_uid=21999779), [Chandler R](http://www.ncbi.nlm.nih.gov/pubmed?term=Chandler%20R&cauthor=true&cauthor_uid=21999779), [Lester R](http://www.ncbi.nlm.nih.gov/pubmed?term=Lester%20R&cauthor=true&cauthor_uid=21999779), [Sheneberger R](http://www.ncbi.nlm.nih.gov/pubmed?term=Sheneberger%20R&cauthor=true&cauthor_uid=21999779), [Tatoud R](http://www.ncbi.nlm.nih.gov/pubmed?term=Tatoud%20R&cauthor=true&cauthor_uid=21999779), [Braithwaite RS](http://www.ncbi.nlm.nih.gov/pubmed?term=Braithwaite%20RS&cauthor=true&cauthor_uid=21999779), [**Springer S**](http://www.ncbi.nlm.nih.gov/pubmed?term=Springer%20S&cauthor=true&cauthor_uid=21999779)**,** [Fidler SJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Fidler%20SJ&cauthor=true&cauthor_uid=21999779), [Lynch S](http://www.ncbi.nlm.nih.gov/pubmed?term=Lynch%20S&cauthor=true&cauthor_uid=21999779), [Mehta S](http://www.ncbi.nlm.nih.gov/pubmed?term=Mehta%20S&cauthor=true&cauthor_uid=21999779), [Bärnighausen T](http://www.ncbi.nlm.nih.gov/pubmed?term=B%C3%A4rnighausen%20T&cauthor=true&cauthor_uid=21999779), [Mastro TD](http://www.ncbi.nlm.nih.gov/pubmed?term=Mastro%20TD&cauthor=true&cauthor_uid=21999779), [Miller V](http://www.ncbi.nlm.nih.gov/pubmed?term=Miller%20V&cauthor=true&cauthor_uid=21999779), [Dukay V](http://www.ncbi.nlm.nih.gov/pubmed?term=Dukay%20V&cauthor=true&cauthor_uid=21999779), [Lima VD](http://www.ncbi.nlm.nih.gov/pubmed?term=Lima%20VD&cauthor=true&cauthor_uid=21999779), [Quan VM](http://www.ncbi.nlm.nih.gov/pubmed?term=Quan%20VM&cauthor=true&cauthor_uid=21999779), [El-Sadr W](http://www.ncbi.nlm.nih.gov/pubmed?term=El-Sadr%20W&cauthor=true&cauthor_uid=21999779), [O'Brian W](http://www.ncbi.nlm.nih.gov/pubmed?term=O'Briain%20W&cauthor=true&cauthor_uid=21999779), [Cunningham WE](http://www.ncbi.nlm.nih.gov/pubmed?term=Cunningham%20WE&cauthor=true&cauthor_uid=21999779), [Anglaret X](http://www.ncbi.nlm.nih.gov/pubmed?term=Anglaret%20X&cauthor=true&cauthor_uid=21999779), [Fleming Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Fleming%20Y&cauthor=true&cauthor_uid=21999779), [Wu Z](http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20Z&cauthor=true&cauthor_uid=21999779). [ART in Prevention of HIV and TB Research Writing Group](http://www.ncbi.nlm.nih.gov/pubmed?term=ART%20in%20Prevention%20of%20HIV%20and%20TB%20Research%20Writing%20Group%5BCorporate%20Author%5D&cauthor=true&cauthor_uid=21999779), Antiretroviral therapy in Prevention of HIV and TB: update on current research efforts. Current HIV Reports 2011. 9 (6); 446-69. PMID: 21999779; PMCID: PMC3531820.
24. Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, **Springer SA**, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS and Behavior, 2011. Nov 8. PMID: 22065234; PMCID: PMC3325326.
25. **Springer SA,** Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Disease, 2011. 53(5): 469-479. PMID: 21844030; PMCID: PMC3156144.
26. Saber Tehrani AS, **Springer SA**, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, Study Design and Sample Characteristics of a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy for HIV-infected Prisoners Transitioning to the Community - Potential Conduit to Improved HIV Treatment Outcomes. Contemporary Clinical Trials. 2012. 33(2):436-44. PMID 22101218; PMCID: PMC3268833.
27. Rich JD. Wohl, DA, Beckwith CG, Spaulding A, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, **Springer SA**. Centers for AIDS Research-Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-related research in correctional populations: Now is the time. Current HIV/AIDS Reports. 2011; 8 (4):288-296. PMID: 21904902; PMCID: PMC3208731.
28. **Springer SA**, Dushaj A, Azar MM**.** The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy among Adult Persons Living with HIV/AIDS: A Systematic Review Article. AIDS Behav 2012. [Epub ahead of print] PMID: 22644066; PMCID: PMC3481055.
29. **Springer SA**, Qiu J, Saber-Tehrani, AS, & Altice, FL. Retention onbuprenorphine is associated with high levels of maximal viral suppressionamong HIV-infected opioid dependent released prisoners. PLoS ONE. 2012; 7(5): e38335. PMID 22719814; PMCID: PMC3365007.
30. Krishnan A, Wickersham JA, Chitsaz E, **Springer SA,** Jordan AO, Zaller N, Altice FL. Post-release substance abuse outcomes among HIV-infected jail detainees: Results from a multisite study. *AIDS Behavior*. 2012. Nov 11. [Epub ahead of print] PMID: 23142854; PMCID: PMC3600070.
31. Meyer J, Wickersham J, Fu JJ, Brown SE, Sullivan T, **Springer S**, Altice F. Partner Violence and Health among HIV-Infected Jail Detainees. International Journal of Prisoner Health. Int J Prison Health. 2013; 9(3): 124–141. PMID: 24376468; PMCID: PMC3873166.
32. Chitsaz E, Meyer JP, Krishnan A, **Springer SA**, Marcus R, Zaller N, Jordan AO,Lincoln T, Flanigan TP, Porterfield J, Altice FL.  Contribution of SubstanceUse Disorders on HIV Treatment Outcomes and Antiretroviral Medication AdherenceAmong HIV-infected Persons Entering Jail.  AIDS and Behavior 2013 May 15. PMID:23673792; PMCID: PMC3818019.
33. **Springer SA,** Altice FL, Herme M, & DiPaola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials. Contemp Clin Trials. 2013 Dec 31;37(2):209-218. PMID: 24384538; PMCID: PMC3992862.
34. Meyer JP, Cepeda J, Wu J, Trestman RL, Altice F**, Springer S**.  Optimization of HIV Treatment during Incarceration: Viral Suppression at the Prison Gate.  JAMA Internal Medicine.  2014 May;174(5):721-9.  doi:10.1001/jamainternmed.2014.601. PMID:24687044; PMCID: PMC4074594.
35. Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, **Springer SA**. Corrigendum to ‘An Evaluation of Hepatic Enzyme Elevations Among HIV-Infected Released Prisoners Enrolled in Two Randomized Placebo-Controlled Trials of Extended Release Naltrexone. Journal of Substance Abuse Treatment. Published online 13 March 2014 . doi:10.1016/j.jsat.2014.02.008. PMID: 28476270; PMCID: PMC5458355.
36. Di Paola A, Altice FL, Powell ML, Trestman RL & **Springer SA.** A Comparison of Psychiatric Diagnoses Among HIV-Infected Prisoners Receiving Combination Antiretroviral Therapy Transitioning to the Community. Health and Justice 2014, 2:11. PMID: 25606368; PMCID: PMC4297667.
37. Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, **Springer SA.** Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 39 (2014) 256-268. PMID: 25240704; PMCID: PMC4283549.
38. Meyer JP, Cepeda J, **Springer S**, Wu J, Trestman R, Altice FL.  HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet HIV, Early Online Publication, 2014.  1(2):e77-e84. [NIHMS: 636511]. PMID; 25473651; PMCID: PMC4249702.
39. Wickersham JA, Azar MM, Cannon CM, Altice FL & **Springer SA**. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). Journal of Correctional Health Care, 2015; 21 (1): 12-26. PMID: 25559628; PMCID: PMC4435561.
40. Lincoln T, Simon-Levine D, Smith J, Donenberg GR, **Springer SA**, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal of Correctional Health Care, 2015; Apr;21(2):125-39. doi: 10.1177/1078345815574566. PMID: 25788608; PMCID: PMC4433291.
41. **Springer SA**, Larney S, Alam Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: Progress, gaps and future directions. J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 1:S155-S161. PMID: 25978482; PMCID: PMC4443704.
42. Lima VD, Graf I, Beckwith CG**, Springer SA**, Altice FL, Coombs D, Kim B, Messina L, Montaner JSG, Spaulding A, for the Seek Test Treat and Retain Corrections (STTaR Corr) Modeling Group**.** The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLoS One. 2015 May 15;10(5):e0128734. doi: 10.1371/journal.pone.0128734. eCollection 2015. PMID: 25978721; PMCID: PMC4433341.
43. Vagenas P, Zelenev A,Altice FL, Di Paola, A, Jordon AO, Teixeira PA, Frew PM, Spaulding AC, **Springer, SA.** HIV-infected Men Who Have Sex with Men, Before and After Release from Jail: The Impact of Age and Race, Results from a Multi-Site Study. AIDS Care. Accepted June 10, 2015. AC-2015-01-0018.R1. PMID: 26275122; PMCID: PMC4713253.
44. Vagenas P, Azar MM, Copenhaver MM, **Springer SA,** Molina PE, Altice FL. [The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of Care.](http://www.ncbi.nlm.nih.gov/pubmed/26412084) Curr HIV/AIDS Rep. 2015 Dec;12(4):421-36. doi: 10.1007/s11904-015-0285-5. PMID: 26412084; PMCID: PMC4643391.
45. **Springer SA**, Brown SE, Di Paola A, Altice, FL. Correlates of Retention on Extended-Release Naltrexone among Persons Living with HIV Infection Transitioning to the Community from the Criminal Justice System. Drug and Alcohol Dependence. 2015 Oct 28. pii: S0376-8716(15)01719-6. doi: 10.1016/j.drugalcdep.2015.10.023. PMID: 26560326; PMCID: PMC4675147.
46. Christopher PP, Stein MD, **Springer SA,** Rich JD, Johnson JE, Lidz CW. An exploratory study of therapeutic misconception among incarcerated clinical trial participants. AJOB Empirical Bioethics. 2016; 7 (1): 24-30.Epub 2015 Jun 24. PMID: 26709382; PMCID: PMC4687735.
47. MakarenkoI, MazhnayaA, PolonskyM, MarcusR, BojkoMJ, FilippovichS, **SpringerS**, DvoriakS, AlticeFL. Determinants of Willingness to Enroll Into Opioid Agonist Therapy among Opioid Dependent People Who Inject Drugs in Ukraine. Drug Alcohol Depend. 2016 Aug 1;165:213-20. doi: 10.1016/**j**.drugalcdep. 2016.06.011. PMID: 27370527; PMCID: PMC5094181.
48. Nance RM, Delaney JA, Golin CE, Wechsberg, WM, Cunningham, C, Altice, F, Christopoulos, K, Knight, K, Quan, V, Gordon, MS, **Springer, S,** Young, J, Crane, PK, Mayer, KH, Mugavero, MJ, Del Rio, C, Kronmal, RA, Crane, HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care. 2017 Apr;29(4):464-468. doi: 10.1080/09540121.**2016**.1263721. PMID: 27910703; PMCID: PMC5291764.
49. Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith C, *Kuo I,* Gordon MS, Altice FL, Ouellet, LJ, Cunningham W, Young JD, **Springer SA**. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS Behav. 2017 Oct;21(10):2945-2957. doi: 10.1007/s10461-017-1722-9. PMCID; PMC5552433
50. **Springer SA**, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017 May 1;174:158-170. doi: 10.1016/j.drugalcdep.2017.01.026. Epub 2017 Mar 10. PMID: 28334661; PMCID: PMC5407009.
51. Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, **Springer SA**, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort Profile: Seek, Test, Treat and Retain United States Criminal Justice Cohort.Subst Abuse Treat Prev Policy. 2017 May 16;12(1):24. doi: 10.1186/s13011-017-0107-4. PMID: 28511680; PMCID: PMC5433052.
52. Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, **Springer SA**, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug Alcohol Depend. 2017 Oct 1;179:213-219. doi: 10.1016/j.drugalcdep.2017.07.010. Epub 2017 Aug 5. PMID: 28806638; PMCID: PMC5599372.
53. Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, **Springer SA**. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Subst Use Misuse. 2018 Jul 29;53(9):1519-1528. doi: 10.1080/10826084.2017.1416400. Epub 2018 Jan 15. PMID: 29333954; PMCID: PMC6432769
54. Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, **Springer SA**. Qualitative Assessment of Attitudes About and Preferences for Extended-Release Naltrexone, a New Pharmacotherapy to Treat Opioid Use Disorders in Ukraine. Journal of Substance Abuse Treatment. 2018 Mar; 86:86-93. PMID: 29415856; PMCID: PMC5808584.
55. **Springer SA**, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634. PMID: 29373393; PMCID: PMC5889326.
56. **Springer SA**, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):92-100. doi: 10.1097/QAI.0000000000001759. PMID: 29781884; PMCID: PMC6092223.
57. Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, **Springer SA**, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLoS One. 2018 May 22;13(5):e0197730. doi: 10.1371/journal.pone.0197730. PMID: 29787580; PMCID: PMC5963777.
58. **Springer SA,** Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann Intern Med. 2019 Apr 2;170(7):509. doi: 10.7326/L19-0042. PMID: 30934074; PMCID: PMC6251491.
59. Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Perez Trejo ME, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, **Springer S**, Chandler R, Kahana S, Crane HM. Reduced use of illicit substances, even without abstinence, is associated with improved depressive symptoms among people living with HIV. J Acquir Immune Defic Syndr 2018 Jul 19. doi: 10.1097/QAI.0000000000001803. PMID: 30036277; PMCID: PMC6681811.
60. Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, **Springer SA**. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug Alcohol Depend. 2019 Jan 1;194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23. PMID: 30412898; PMCID: PMC6312501.
61. Fanucchi L, **Springer SA,** Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV [Curr HIV/AIDS Rep.](https://www.ncbi.nlm.nih.gov/pubmed/30684117) 2019 Feb;16(1):1-6. doi: 10.1007/s11904-019-00436-7. PMID: 30684117; PMCID: PMC6420833.
62. **Springer SA**, Korthuis PT, Del Rio C. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Response Letter. [Ann Intern Med.](https://www.ncbi.nlm.nih.gov/pubmed/30934074) 2019 Apr 2;170(7):509. doi: 10.7326/L19-0042. PMID: 30934074.
63. Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice FL, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, *Kuo I*, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, **Springer S**, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clin Infect Dis. 2020 Feb 14;70(5):867-874. doi: 10.1093/cid/ciz299. PMID: 30994900; PMCID: PMC7319266
64. Makarenko J**,** Pykalo P; **Springer SA**; Mazhnaya A; Marcus R; Filippovich S; Dvoriak S; Altice FL**.** Treating Opioid Dependence With Extended-Release Naltrexone (XR-NTX) in Ukraine: Feasibility and Three-Month Outcomes. J Subst Abuse Treat. 2019 Sep;104:34-41. doi: 10.1016/j.jsat.2019.05.008. Epub 2019 May 10. PMID: 31370983
65. Biondi BE, Frank C, **Springer SA**. Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research? J Addict Med. 2020 May/Jun;14(3):182-184. doi: 10.1097/ADM.0000000000000565. PMID: 31403523; PMCID: PMC7059864.
66. Serota D, Baracos JA, **Springer S.** Infectious complications of addiction: A call for a new subspecialty within infectious diseases. Clin Infect Dis. 2020 Feb 14;70(5):968-972. doi: 10.1093/cid/ciz804. PMID: 31420651; PMCID: PMC7319263.
67. Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman F, Altice FL, Delaney J, Crane H, **Springer SA**. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. *BMC Infect Dis*. 2019;19(1):913. Published 2019 Oct 29. doi:10.1186/s12879-019-4443-z. PMID: 31664910; PMCID: [PMC6819597](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6819597/%22%20%5Ct%20%22_blank)
68. Biondi BE, Frank C, Horn BP, **Springer S**. Reduced Sexual Risk Behaviors among Persons with HIV After Release from the Criminal Justice System. Open Forum Infect Dis. 2019 Sep 21;6(10):ofz411. doi: 10.1093/ofid/ofz411. PMID: 31660369; PMCID: PMC6788338.
69. **Springer SA**, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic Among Women. J Addict Med. 2020 Sep/Oct;14(5):364-366. doi: 10.1097/ADM.0000000000000622. PMID: 32011410; PMCID: PMC7392801.
70. Seval N, Eaton E, **Springer SA**. Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. Open Forum Infect Dis. 2019 Dec 24;7(1):ofz539. doi: 10.1093/ofid/ofz539. PMID: 31993454; PMCID: PMC6979000.
71. **Springer SA**, Rio CD. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. *Infect Dis Clin North Am*. 2020;34(3):637-647. doi:10.1016/j.idc.2020.06.015. PMID: 32782106; PMCID: PMC7414693.
72. **Springer SA**, Rio CD. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. *Infect Dis Clin North Am*. 2020;34(3): :xiii-xiv. PMID: 32782107; PMCID: PMC7414777
73. Seval N, Wurcel A, Gunderson CG, Grimshaw A, **Springer SA**. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review. Infect Dis Clin North Am. 2020 Sep;34(3):559-584. doi: 10.1016/j.idc.2020.06.011. PMID: 32782102; PMCID: PMC7437982.
74. **Springer SA**, Merluzzi AP, Del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA. 2020 Jul 7;324(1):37-38. doi: 10.1001/jama.2020.2559. PMID: 32159771; PMCID: PMC7957328.
75. Biondi BE, Zheng X, Frank CA, Petrakis I, **Springer SA**. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? *Am J Addict*. 2020;29(4):249-267. doi:10.1111/ajad.13051
76. JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, **Springer SA**, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS. 2020 Dec 1;34(15):2285-2294. doi: 10.1097/QAD.0000000000002716. PMID: 33048870; PMCID: PMC7951611.
77. **Springer SA**, Masciotra S, Johnson JA, Campbell S. Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing. Open Forum Infect Dis. 2020 Oct 10;7(11):ofaa478. doi: 10.1093/ofid/ofaa478. PMID: 33204760; PMCID: PMC7651562.
78. Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, **Springer SA**. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021 Jan 6;21:100704. doi: 10.1016/j.conctc.2021.100704. PMID: 33490708; PMCID: PMC7807244.
79. Biondi BE, Frank CA, Forray A, **Springer SA**. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment. Subst Abus. 2021 Mar 22:1-7. doi: 10.1080/08897077.2021.1900984. Epub ahead of print. PMID: 33750285.
80. Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, **Springer SA**. Preventing HIV outbreaks among people who inject drugs in the United States: Plus ça change, plus ça même chose [published online ahead of print, 2020 Aug 20]. *AIDS*. 2020;10.1097/QAD.0000000000002673. doi:10:1097/QAD.0000000000002673 PMID: 32826391; PMCID: PMC7606503.
81. **Springer SA**, Barocas JA, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda. J Infect Dis. 2020 Sep 2;222(Supplement\_5):S230-S238. doi: 10.1093/infdis/jiz673. PMID: 32877568; PMCID: PMC7467230.
82. Cioe K, Biondi BE, Easly R, Simard A, Zheng X, **Springer SA**. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020 Dec;119:108146. doi: 10.1016/j.jsat.2020.108146. Epub 2020 Sep 22. PMID: 33138929; PMCID: PMC7609980.
83. Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, **Springer SA**, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS. 2020 Dec 1;34(15):2285-2294. doi: 10.1097/QAD.0000000000002716. PMID: 33048870; PMCID: PMC7951611.
84. Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, **Springer SA**. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemp Clin Trials. 2021 Apr 7;105:106394. doi: 10.1016/j.cct.2021.106394. Epub ahead of print. PMID: 33838307.
85. Waddell EN, **Springer SA**, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monica L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abuse Treat. 2021 Apr 8:108389. doi: 10.1016/j.jsat.2021.108389. Epub ahead of print. PMID: 33865691.
86. Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, **Springer SA**. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. The International Journal on Drug Policy. 2021 May:103283. DOI: 10.1016/j.drugpo.2021.103283.
87. Katelyn F McNamara, BS, Breanne E Biondi, MPH, Raúl U Hernández-Ramírez, PhD, Noor Taweh, Alyssa A Grimshaw, MSLIS, **Sandra A Springer, MD**, A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes, Open Forum Infectious Diseases, Volume 8, Issue 8, August 2021, ofab289, <https://doi.org/10.1093/ofid/ofab289>

**Chapters, Books, and Reviews**

1. **Springer SA**. Fever of Unknown Origin in *Field Guide to Internal Medicine.* Eds, Smith D, Sullivan L & Haye S.Lippincott, Williams & Wilkins. 2004.
2. **Springer SA**. Human Immunodeficiency Virus in *Field Guide to Internal Medicine.* Eds, Smith D, Sullivan L & Haye S.Lippincott, Williams & Wilkins. 2004.
3. **Springer SA**. Alcohol & Illicit Drug Withdrawal/Overdose in *Field Guide to Internal Medicine.* Eds, Smith D, Sullivan L & Haye S. Lippincott, Williams & Wilkins. 2004.
4. Altice FL & **Springer SA**. "Overview of HIV Care and Antiretrovirals." Clinical Practice in Correctional Medicine, 2nd edition. Puisis M. ed. Elsevier Inc. San Diego, CA. 2005.
5. Altice FL & **Springer SA**. “Management of HIV/ AIDS in Correctional Settings.” The AIDS Pandemic: Impact on Science and Society. Mayer K, Pfizer HF. Eds. Elsevier Inc. San Diego, CA. 2005.
6. **Springer SA** & Altice FL. Improving Care for HIV infected Prisoners Released to the Community: An Integrated Health Model in:Public Health is Public Safety: Improving Public Health through Correctional Health Care. Greifinger RB (Ed) Springer Inc. New York. 2007.
7. Cepeda J & **Springer SA**. Drug and Alcohol Dependence in the United States Criminal Justice System. Encyclopedia of Criminology and Criminal Justice. Binswanger & Taxeman F (Eds). Springer Inco. New York 2013.
8. Copenhaver M, Baldwin P, **Springer SA,** Ezeabogo I, & Altice FL**.** HIV prevention and care among drug-involved HIV-infectedprisoners transitioning to the community. Reentry Planning for Offenders with Mental Disorders:Policy and Practice, Vol. II. Dulgacz, DA (Ed).Civic Research Institute. Kingston, NJ 2013.
9. Nabila El-Bassel, Phillip L. Marotta, MSc, Louisa Gilbert, Elwin Wu, **Sandra Springer**, Dawn Goddard-Eckrich, Timothy Hunt. Integrating treatment for opioid use disorders and HIV services into Primary Care: Solutions for the 21st Century. May 2018.
10. Seval N, Eaton E, **Springer SA**. Inpatient Opioid Use Disorder (OUD) Treatment for the Infectious Disease Physician. In *The Opioid Epidemic and Infectious Diseases* (Edited by Brianna Norton). Elsevier Inc. March 1, 2020.

**Invited Editorials and Commentaries**

1. **Springer, SA**. Improving healthcare for incarcerated women. J Womens Health (Larchmt). 2010 Jan;19(1):13-5. doi: 10.1089/jwh.2009.1786. PMID: 20088653; PMCID: PMC2828190.
2. **Springer SA.** Commentary on Larney (2010):A call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction. 2010 Feb;105(2):224-5. doi: 10.1111/j.1360-0443.2009.02893.x. PMID: 20078481; PMCID: PMC2825564.
3. **Springer SA**. A Commentary: High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada. Evidence Based Mental Health. 2012 Feb; 15(1):9. Doi: 10.1136/ebmh.2011.100199. Epub 2011 Nov 1. PMID: 22044870.
4. **Springer, S.** HCV reinfection is low among persons who use drugs maintained on medication treatment for Opioid Use Disorder. Invited Editorial Commentary. Clin Infect Dis. 2019 Jul 26:ciz695. doi: 10.1093/cid/ciz695. Online ahead of print. PMID: 31346595
5. **Springer S.** Aortic Valve Surgery Outcomes Reporting and Implications for Persons who Use Drugs with Infective Endocarditis. Invited Editorial Commentary. Clin Infect Dis. 2019 Oct 7:ciz837. doi: 10.1093/cid/ciz837. Online ahead of print. PMID: 31588502
6. **Springer SA** & Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clin Infect Dis. 2020 Oct. 23;71(7):1723-1725. doi: 10.1093/cid/ciaa111. PMID: 32011653; PMCID: PMC7583407.
7. Del Rio C & **Springer SA**. Hepatitis C in the United States: One Step Forward, Two Steps Back. Am J Public Health. 2021 May;111(5):768-769. doi: 10.2105/AJPH.2021.306251. PMID: 33826392; PMCID: PMC8033994.
8. **Springer SA**. Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder? Addiction. 2021 Sep 22. doi: 10.1111/add.15668. Epub ahead of print. PMID: 34549844.

**Case Reports, Technical Notes, Letters**

1. **Springer SA** & Altice FL. Human immunodeficiency virus infection with human granulocyte ehrlichiosis complicated by symptomatic lactic acidosis. Clinical Infectious Diseases 2003 Jun 15; 36(12):e162-4. [PMID: 12802782]
2. Altice FL, **Springer SA** & Pesanti E. Reply to Badudieri et al. Clinical Infectious Diseases 2004;39.
3. Altice FL, **Springer SA**. DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for non-adherence and use of untested interventions. Arch Internal Medicine. 2010; 170(1):109-10. PMID: 20065210; PMCID: PMC2825565.
4. **Springer SA.** Extended-Release Naltrexone for HIV+ Released Prisoners. Alcoholism Clinical & Experimental Research 2012. Supplement 36 (6); 342A. No. 156.

**Educational Resources:**

1. **Springer SA.** Hepatitis B and C Prevention and Treatment in Persons who Use Drugs. Webinar For PCSS MAT training. October 27, 2014. **Revised and Updated October 2017**. <http://pcssmat.org/education-training/modules/aaap-online-module-hepatitis-c-and-b-prevention-and-treatment-in-persons-who-use-drugs/>
2. **Springer SA**. Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone. PCSS Educational Information. October 27, 2014. **Revised and Updated October 2017**. <http://pcssmat.org/new-clinical-guidance-posted-monitoring-of-liver-function-tests-in-patients-receiving-naltrexone-or-extended-release-naltrexone/>
3. **Springer SA.** Advancing Antiretroviral Therapy for HIV: Tailoring a Regimen for the Treatment-Experienced Patient Webinar as part of the **2014 HIV Summit Series: Clinical Challenges in HIV Management: A Two-Part Educational Series. Penn State Hershey College of Medicine.** December 9, 2014. <https://event.webcasts.com/viewer/directLink.jsp?ei=1050240>
4. **Springer SA.** Drug treatment to improve the HIV continuum of care for Women who use drugs: progress, gaps, and future directions. Web-based education. SAMHSA. April 27, 2016
5. **Springer SA**, Bisaga A, Training. PCSSPM. XR-Naltrexone: A Step-by-Step Guide. In: Providers Clinical Suport Services (PCSS) Projects AAoAPA, ed. East Providence, Rhode Island, USA2017.
6. **Sandra A. Springer**, Invited Contributor to Substance Abuse and Mental Health Services Administration (SAMHSA), (NIDA). Advances in Non-agonist Therapies. Collaborator. In: U.S. Department of Health and Human Services SAaMSA, Center for Substance Abuse Treatment, ed. Rockville, MD: U.S. DHHS; 2016:1-50.
7. American Society of Addiction Medicine (ASAM). **Sandra A. Springer, MD, invited co-member of writing group**. Policy on Hepatitis C Diagnosis and Treatment among persons who use Drugs. October 2016. <https://urldefense.proofpoint.com/v2/url?u=https-3A__www.asam.org_docs_default-2Dsource_public-2Dpolicy-2Dstatements_pdff5b01a9472bc604ca5b7ff000030b21a.pdf-3Fsfvrsn-3D0&d=DwMFAg&c=-dg2m7zWuuDZ0MUcV7Sdqw&r=ZopE7HOKuU2n8SXi_pzFgKRQ-ELYdmO9zoe94a6WH9k&m=AQ6RlUCpcrpSBY-Q8QKgMasKr8Yc8xuyHjzG0zSgS2g&s=99gsh42L047R1hCcwGFXeaNYvlrhQPPEUyzxBKdIc04&e>=
8. HIV/HCV Virtual Roundtable. **Springer SA**, Brady K, Litwin A. July 2019. DDK MD Inc. **Link:**[**https://spaces.hightail.com/receive/NF9g9yPCds**](https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fspaces.hightail.com%2Freceive%2FNF9g9yPCds&data=02%7C01%7Csandra.springer%40yale.edu%7C4d82dca172e44380798f08d757bcad3d%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637074340184526140&sdata=1mdVzmA4kXbZZNFZgA7ZOb4rS%2B6O6LsMXtHa2sRDMTw%3D&reserved=0)
9. Clinical Care Options (CCO) Education training video. **Springer S** & Rammers C. Benefits of and Need for Integrated Addiction and Infectious Disease Care. December 2019.

<https://www.clinicaloptions.com/hiv/programs/addiction-hcv-hiv>

<https://www.clinicaloptions.com/hiv/programs/addiction-hcv-hiv/podcast/podcast-1>

1. National Academy of Sciences, Engineering and Medicine (NASEM) Consensus Study Report. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services. January 20, 2020. **Sandra A. Springer, MD member of appointed committee**

<https://www.nap.edu/read/25626/chapter/1>

1. ASAM’s National Practice Guidelines for Treatment of Opioid Use Disorders. April 2020. **Sandra A. Springer, MD member of appointed committee.** <https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2>
2. Clinical Care Options (CCO) Clinical Thought. Integrating OUD Screening, Diagnosis and Medical Treatment into ID Care. Educational Session. **Sandra A. Springer, MD.** June 25, 2020. <https://www.clinicaloptions.com/hepatitis/programs/addiction-hcv-hiv/clinicalthought/ct2/page-1>
3. **Course Director.** **Sandra A. Springer, MD.** Clinical Care Options and American Society of Addiction Medicine (ASAM). Incorporating HIV/HCV Prevention, Screening, and Linkage to Care Into Opioid Use Disorder Treatment Settings. July 2020. <https://elearning.asam.org/products/incorporating-hivhcv-prevention-screening-and-linkage-to-care-into-opioid-use-disorder-treatment-settings#tab-product_tab_contributors>
4. Opioid Use Disorder Treatment in time of COVID19. PODCAST**. Sandra A. Springer, MD** & Michael Frost, MD. Titan. [https://vimeo.com/438502075](https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fvimeo.com%2F438502075&data=02%7C01%7Csandra.springer%40yale.edu%7Cb0bfa935d78a45f5d4a608d828eeb799%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637304353035428250&sdata=a%2BgIzzFvjEow%2FOrFdiiihZw%2FC%2F1owvpaUYb3QjmwU3c%3D&reserved=0) (PW: btk123). August 2020.
5. *What’s New with the Flu ’2020-2021*. **Sandra A. Springer, MD.** Video Interview. DKBmed. September 18, 2020.
6. HIV Learning Lab. CME Educational Session. DKBmed, LLC. **Sandra A. Springer, MD**. Webinar. September 10, 2020.
7. Integrating Buprenorphine Treatment Into Infectious Disease Settings. **Sandra A. Springer, MD**. Recorded Educational Program. Opioid Learning Institute and DC Health. September 21, 2020.
8. American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) Pocket Guides for*Treatment Court Clinicians, Non-Clinicians and Treatment Court Participants.* **Invited co-writer, Sandra A. Springer, MD**. September 25, 2020.
9. HIV Treatment: New Guidelines and Evidence to Support Faster ART Initiation. CME Educational Recorded Live Webinar. **Sandra A. Springer, MD** & Marc O Siegel, MD and Melissa Badowski, Pharm D. PRIME and ViiV Healthcare. November 12, 2020. <https://primeinc.org/programs/hd/80WB203?nopre=1>
10. Raising the Bar in HIV Standards of Care: A 4-Part Video Podcast Series for Providers in Federal & Public Healthcare Settings. Jason M Blaylock, MD, FACP, FIDSA, CTropMed; Gregory S Felzien, MD, AAHIVS; **Sandra A Springer, MD**. Treatment Decision-Making for the Aging Veteran Living with HIV: **Sandra A Springer, MD** & Jason M Blaylock, MD, FACP, FIDSA. PRIME Inc., Sponsored by Gilead Sciences Inc. June 18, 2021. <https://primeinc.org/programs/hd/54PC214?nopre=1>

**Scholarship in Press:**

1. .Fredericksen RJ. Whitney BM. Trejo E. Nance RM. Fitzsimmons E. Altice FL. Carrico AW. Cleland CM. Del Rio C. Drumright L. Duerr A. El-Sadr WM. Kahana S. Kuo I. Mayer K. Mehta S. Ouellet LJ. Quan VM. Rich J. Seal DW. **Springer S.** Taxman F. Wechsberg W. Crane HM. Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort.BMC Public Health. IN PRESS.
2. Poland C, Sadacharan R**, Springer SA**. Care for Special Populations: People in the Justice System. In Addiction Medicine Pocket Guide (American Society of Addiction Medicine (ASAM)). Editors: Wakeman S, Alvanzo A, & Lee J. April 23, 2021. **In Press**.

**Media**

Sandra A. Springer, MD <https://health.usnews.com/doctors/sandra-springer-221393>

Director of **InSTRIDE** –Integrating Substance Use Treatment Research with Infectious Disease for Everyone <https://medicine.yale.edu/lab/springer/>

1. Healio News: Combining treatment for opioid use disorder, HIV improves viral suppression, ART adherence (June 25, 2021): <https://www.healio.com/news/infectious-disease/20210622/combining-treatment-for-opioid-use-disorder-hiv-improves-viral-suppression-art-adherence?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=1655425680739>
2. Coming up short: Court driving NC prisons reform, but expert advice on handling pandemic still rejected (December 16, 2020) <https://carolinapublicpress.org/40730/coming-up-short-court-driving-nc-prisons-reform-but-expert-advice-on-handling-pandemic-still-rejected/>?
3. HIV Treatment: New Guidelines and Evidence to Support Faster ART Initiation (December 11, 2020) <https://primeinc.org/online/hiv-treatment-new-guidelines-evidence-support-faster-art-initiation?utm_source=primefac&utm_medium=springer&utm_campaign=80WB203>
4. IDSA Media Briefing: COVID-19 in Correctional Facilities (December 5, 2020) <https://www.idsociety.org/es/multimedia/videos/idsa-media-briefing-may-12-2020/>
5. Pharmacotherapy Webinar featuring Dr. Sandra Springer, Yale AIDS Program (November 20, 2020) <https://www.niaaa.nih.gov/news-events/meetings-events-exhibits/pharmacotherapy-webinar-featuring-dr-sandra-springer-yale-aids-program>
6. $11.5M Grant Supports Study of Linkage To Community-Based Opioid Addiction and HIV Prevention and Treatment Services for Persons Released From Prison (October 5, 2020) <https://medicine.yale.edu/lab/springer/news-article/27800/>
7. The ASAM National Practice Guideline 2020 Focused Update Webinar- Individuals in the Criminal Justice System (September 10, 2020) <https://elearning.asam.org/products/the-asam-national-practice-guideline-2020-focused-update-webinar-individuals-in-the-criminal-justice-system>
8. Tweet by CCO Infectious Disease on Twitter (July 24, 2020) <https://twitter.com/CCO_InfDis/status/1286750233511297026>
9. Benefits of and Need for Integrated Addiction and Infectious Disease Care (July 9, 2020) <https://www.clinicaloptions.com/infectious-disease/programs/addiction-hcv-hiv/podcast/podcast-1>
10. Experts expect more prison COVID-19 deaths without more testing (May 18, 2020) <https://carolinapublicpress.org/30482/experts-expect-more-prison-deaths-covid-19/>
11. ‘One day they came in and told us we had to stay inside because of a virus’ (May 14, 2020) <https://www.wtsp.com/article/news/investigations/10-investigates/one-day-they-came-in-and-told-us-we-had-to-stay-inside-because-of-a-virus/67-30a076a2-9b07-4a04-b89d-1ab194f5d603>
12. How Can Jails Keep COVID-19 at Bay? ID Specialists Weigh In (May 14, 2020) <https://www.medpagetoday.com/infectiousdisease/covid19/86492>
13. IDSA Media Briefing: COVID-19 in Correctional Facilities (May 12, 2020) <https://www.idsociety.org/multimedia/videos/idsa-media-briefing-may-12-2020/>
14. Study shows benefits of treating opioid addiction, HCV at same time (February 14, 2020) <https://www.healio.com/news/infectious-disease/20200214/study-shows-benefits-of-treating-opioid-addiction-hcv-at-same-time>
15. Introduction and Overview of the Intersection Between Opioid Use Disorder and Infectious Disease (February 6, 2020) <https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.clinicaloptions.com%2Fhepatitis%2Fprograms%2Faddiction-hcv-hiv%2Fvideo-module%2Fvideo-module&amp;data=02%7C01%7Csandra.springer%40yale.edu%7Cb64334a10f2441f8c51f08d7b022332a%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637171533242244775&amp;sdata=i8pIPCwg7w6AjJt18S2UnVYcJ19qOLZ1xck3nGtkB9A%3D&amp;reserved=0>
16. Low HIV transmission among recently incarcerated individuals living with HIV and SUDs (September 29, 2019) <https://www.healio.com/news/infectious-disease/20190927/low-hiv-transmission-among-recently-incarcerated-individuals-living-with-hiv-and-suds>
17. The Opioid and Associated HIV Epidemics: Why Understanding Sex and Gender Differences in Medication Treatment for OUD Matter (April 30, 2019)
18. Opioid Use Disorder Should Be Thought of Like an Infectious Disease, Experts Say (April 29, 2019) <https://www.contagionlive.com/view/opioid-use-disorder-should-be-thought-of-like-an-infectious-disease-experts-say>
19. Yale Researcher Awarded $40 Million to Study Opioid Addiction Treatments (March 29, 2019) <https://medicine.yale.edu/news-article/19726/>
20. Researchers win $40 million to study opioid addiction (March 29, 2019) <https://yaledailynews.com/blog/2019/03/29/researchers-win-40-million-to-study-opioid-addiction/>
21. The opioid crisis: ‘We still have a lot of work to do’ (August 16, 2018) <https://www.msnbc.com/ali-velshi/watch/the-opioid-crisis-we-still-have-a-lot-of-work-to-do-1300537411537>
22. Integration of Opioid, Infectious Disease Treatment Needed (August 15, 2018) <https://www.empr.com/home/news/integration-of-opioid-infectious-disease-treatment-needed/>
23. Proposed: Screen Patients with Certain Infections for Opioid Addiction (July 14, 2018) <https://www.medpagetoday.com/neurology/opioids/74027>
24. Within opioid abuse epidemic, infectious disease epidemic emerges (July 13, 2018) <https://www.reuters.com/article/us-health-opioids-infections/within-opioid-abuse-epidemic-infectious-disease-epidemic-emerges-idUSKBN1K32WM>
25. Lessons from HIV epidemic could help address opioid abuse (July 13, 2018) <https://www.healio.com/news/primary-care/20180713/lessons-from-hiv-epidemic-could-help-address-opioid-abuse>
26. Yale study: Drug for opioid, alcohol abuse may help suppress HIV (June 4, 2018) <https://www.middletownpress.com/health/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-12966950.php>
27. Yale study: Drug for opioid alcohol abuse may help suppress HIV (June 4, 2018) <https://www.nhregister.com/news/article/Yale-study-Drug-for-opioid-alcohol-abuse-may-14527724.php>
28. This drug to treat alcohol addiction may become the next weapon in the fight against HIV (June 11, 2018) <https://www.lgbtqnation.com/2018/06/drug-treat-alcohol-addiction-may-become-next-weapon-fight-hiv/>
29. Naltrexone improves HIV care in freed inmates (March 12, 2018) <https://www.healio.com/news/infectious-disease/20180312/naltrexone-improves-hiv-care-in-freed-inmates>